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Abstract 
Low-magnitude high-frequency vibration (LMHFV), a noninvasive and systemic 
biophysical intervention, improved bone healing, accelerated callus formation and 
mineralization of the closed femoral fracture in young female rats, and adult osteo-
porotic or nonosteoporotic female rats. LMHFV treated rats showed larger callus 
size in the middle of treatment period. At the end of treatment, faster remodeling 
was observed and the callus size was comparable to sham. However, the influence 
of LMHFV on bone remodeling was not full understood due to insufficient informa-
tion. Therefore, the effect of LMHFV on fracture healing of osteoporotic rats during 
bone remodeling was investigated in the presence of ibandronate, which functioned 
as an antagonist to bone remodeling. Bisphosphonate suppresses bone resorption 
and lead to uncoupling of bone formation and resorption in bone remodeling. This 
causes inhibition of bone remodeling. Our hypothesis was that LMHFV enhances 
callus remodeling during fracture healing. 
Closed femoral fracture was created in nine-month old ovariectomy-induced os-
teoporotic Sprague-Dawley rats. The rats were randomly assigned into one of four 
treatment groups (Sham (CG), LMHFV only (VG), ibandronate only (BG), or both 
LMHFV and ibandronate (VBG)). Each treatment group had four different treat-
ment durations (2, 4, 6, or 8 weeks). The changes of bone remodeling in fracture 
healing was investigated with respect to radiological, microarchitectural, histomor-
phometrical, and biochemical analyses. In addition, the differences among treat-
ment groups and the interactions of the two treatments were investigated by one-
way ANOVA with bonferonni post-hoc test and two-way ANOVA respectively. 
VG had the fastest drop in callus area and width, and bone volume to tissue 
volume ratio (BV/TV); whereas, a plateaued trend in BG and VBG was observed. 
With respect to callus mineralization, VG had the highest mineral apposition rate 
(MAR) at week 6. Biochemical analyses of bone markers found that the serum 
concentration of bone formation marker (osteocalcin) and bone resorption marker 
(Tartrate-resistant acid phosphatase (TRAP5b)) were higher compared to other 
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groups at week 8. 
The fastest callus reduction indicated that LMHFV enhanced bone remodel-
ing. The highest mineral apposition rate suggested that LMHFV enhanced callus 
mineralization, an important process in callus remodeling. The increased serum 
concentration of osteocalcin and TRAP5b in VG implied increased osteoblast and 
osteoclast activity. This increase in cellular activity is associated with enhanced 
remodeling. Furthermore, LMHFV partially reversed the inhibition of bone remod-
eling by ibandronate suggested LMHFV had an opposite effect on bone remodeling 
to ibandronate. 
In conclusion, the hypothesis that LMHFV accelerated fracture healing by en-
hancing callus remodeling is confirmed. This study helped to understand the mech-
anism of fracture healing enhancement by LMHFV and the effect of LMHFV on 
bone remodeling. The enhanced remodeling by LMHFV might have great potential 
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1.1 Bone and its Cellular Componen t s 
Bone is a dynamic and well-organized structure in the body. At a microscope level, 
bone is made up of cells which are housed in bone matrix. The bone matrix includes 
organic and inorganic components. At a cellular level, bone cells, which contribute 
to the maintains of bone, includes osteoblast, osteoclast, and osteocytes. At a 
macroscopic level, there are two types of bone, woven bone and lamellar bone. 
Woven bone is considered as immature bone while lamellar bone is mature bone. 
Lamellar bone has better mechanical strength compared to woven bone. In addition, 
lamellar bone and woven bone form two marco bone structure: cortical bone and 
trabecular bone. These two type of organization of bone have different mechanical 
strength. All these different levels of organization are the contributing factors to 
the overall mechanical of the bone. 
1.1.1 Cellular Components of Bone 
Bone is one of the hardest substances in the body. Bone is the primary structure 
framework that supports and protects the organs, such as the brain, lungs and heart, 
in the body[49]. The bones also act as a levers for the muscles attached to them 
and also serve as a reservoir for several minerals such as calcium[49]. 
1 
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Bone is a specialized connective tissue with a calcified extracellular matrix. This 
extracellular matrix is composed of fibers (primarily collagen type I) and ground 
substance (rich in proteoglycans and glycoproteins such as osteocalcin). The bone 
matrix has inorganic (composed of mostly calcium and phosphorus，known as cal-
cium hydroxyapatite) and organic constituents (90% collagen type I). The glyco-
proteins such as osteocalcin bind to hydroxyapatite. The hardness and strength of 
bone are due to this association of the calcium hydroxyapatite and collagen[49]. 
The external surface of bone, except the synovial articulations, is covered with 
periosteum, an outer layer of dense fibrous connective tissue and an inner cellular 
layer of osteoprogenitor cells[49]. The endosteum, a thin layer of connective tissue 
which consists of osteoprogenitor cells and osteoblast, lines the central cavity of 
bone[49]. 
Osteoblast 
The bone cells are lying within the extracellular matrix. These cells include os-
teoblast, osteoclast, and osteocytes. Osteoblasts are differentiated from osteopro-
genitor cells. Osteoblast is defined as a cell that produces osteoid or bone matrix. 
These bone forming cells are responsible for synthesis of the organic constituents of 
bone matrix. When osteoblasts are surrounded by the calcified matrix, they become 
osteocytes. Osteoblasts are responsive to parathyroid hormone (PTH) and produce 
osteocalcin. 
Osteocytes 
Osteocytes are the most abundant bone cells. After osteoblasts secreted matrix 
and the bone matrix calcifed, osteoblast differentiated into osteocytes. Osteo-
cytes are matured osteoblasts that are trapped in the calcified matrix called la-
cunae. Osteocytes have extensive cell processes that establish contact with adja-
cent osteocytes[33]. Osteocytes secret substances for bone maintenance and cellular 
regulation of calcium exchange[33]. Osteocytes also have also been implicated in 
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mechanotransduction and serve as mechanosensors [20, 49, 65]. 
Osteoclast 
Osteoclasts are multinucleated giant cells (20 - 100jum) and are responsible for bone 
resorption[49]. Osteoclasts are differentiated from hematopoietic stem cells from 
bone marrow, which can also differentiated Into monocytes and macrophages[15, 33]. 
Osteoclast is located in regions of bone resorption called Howships lacunae (Figure 
1.1)[15, 33]. Another major apparent feature of osteoclast is the extensive foldings 
of cell membrane at region of bone resorption. These cell membrane foldings are 
known as ruffled border[15, 33]. During bone resorption, osteoclast secrets hydrogen 
ion by carbonic anhydrase system to lower the pH of the resorption region. This 
would increase the solubility of apatite crystals. After the mineral is removed, the 
organic components of the matrix is broken down by proteolytic digestion[15, 33]. 
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Figure 1.1: Bone resorption by osteoclast[48]. The cell membrane of osteoclast is folded 
into ruffled border. The resorption region is known as Howships lacunae. (Reprinted from 
Ganong et al. 2009)[48] 
The bone resorption activity is regulated by two hormones, PTH and calcitonin[15, 
49]. PTH is produced by parathyroid gland and it stimulates bone resorption which 
leads to increase of serum calcium concentration. On the other hand, calcitonin 
is produced by thyroid gland and it suppresses bone resorption which decreases 
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calcium concentration[15]. 
1.1.2 Macroscopic Structure 
Cortical bone has four times the mass of trabecular bone but the metabolic turnover 
of trabecular bone is eight time higher than cortical bone. Since bone turnover 
happens on the bone surface, the trabecular bone has a faster bone turnover rate 
than cortical bone is because trabecular bone has larger bone surface compared to 
cortical bone[33]. 
Cortical Bone 
Cortical bone composes the diaphysis of long bone and envelopes the cuboid bones[33]. 
Mechanical stress that cortical bone is subjected to is bending and torsional forces, 
and compression forces. In small animals, the cortical bone does not have special 
arrangement for the vascular network. However, in larger animals, the cortical bone 
is made up of layers of lamellar bone and woven bone while the vascular channels 
are located in the woven bone[33]. 
Trabecular Bone 
Trabecular bone is found at the metaphysis and epiphysis of long bone and cuboid 
bones[15, 33]. Trabecular bone forms three-dimensional branching lattice in area 
of mechanical stress. The predominate mechanical stress that trabecular bone is 
subjected seems to be compression. 
1.1.3 Microscopic Structure 
As mentioned previously, there are two different organization of both structure, 
which is cortical bone and trabecular bone. Woven bone and lamellar bone can be 
found in both cortical bone and trabecular bone. 
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Woven Bone 
At the microscopic level, there are two forms of bone: woven bone and lamellar 
bone. Woven bone is normally found in the embryo and the newborn, metaphyseal 
region of growing bone, and fracture callus[15, 33]. Also, it is found in tumors, 
osteogenesis imperfecta, and pagetic bone. Woven bone is considered as primitive 
and immature bone. It contains no uniform orientation of the collagen fibers. The 
mineral content and cells in woven bone are randomly arranged[15, 33]. Woven 
bone has an isotropic mechanical characteristic because the random orientation of 
collagen fibers. Therefore, mechanical characteristics of woven bone would be similar 
regardless the orientation of forces applied[33]. 
Lamellar Bone 
Lamellar bone is relatively more mature than woven bone[33]. Lamellar bone is 
formed from remodeling of woven bone. Lamellar bone begins to form one month 
after birth and would eventually replace most of the woven bone by four years 
old. Lamellar bone is found in mature skeleton in both trabecular and cortical 
bone[15, 33]. The collagen fiber in lamellar bone is highly organized and oriented 
with the direction of stress. Therefore, lamellar bone has an isotropic mechanical 
characteristic and the greatest strength would be parallel to the longitudinal axis of 
the collagen fibers[33]. 
1.2 Frac tu re Healing 
Fracture healing is a complex and ordered process that involves coordination of many 
different processes[33,126]. These processes resemble those that are found in skeletal 
development and growth[33, 126].This repairing process is different from repair of 
other tissue because a fracture is repaired by bone instead of a scar tissue[33j. 
Therefore, after a fracture is healed, the preexisting properties of the bone are 
restored[33]. Fracture healing involves a series of regenerative processes which begin 
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at the moment of fractures[33]. This complex process is conventionally divided into 
four stages as a result of histological observations. Each stage is characterized by 
a specific cellular and molecular event (Figure 1.3)[33, 126]. The four stages are 
inflammation, soft callus formation, hard callus formation, and bone remodeling 
(Figure 1.2[33, 126]. 
1.2.1 Inf lammation 
A fracture caused the disruption of the integrity of soft tissue, vascular function 
and marrow architecture. The local bleeding at the fracture site develop into 
a hematoma. This hematoma signals the infiltration of degranulating platelets, 
macrophages, and other inflammatory cells such as granulocytes, lymphocytes, and 
monocytes[33, 126]. The inflammatory cells would secret cytokines that are im-
portant in regulating the early stages of fracture healing. These cells would also 
secret growth factors which would recruit additional inflammatory cells in a positive 
feedback loop. These growth factors and cytokines would lead to invasion of multi-
potent mesenchymal stem cells which orginated from the periosteum, bone marrow, 
circulation, and surrounding soft tissues (Figure 1.2a)[126]. 
1.2.2 Soft Callus Formation 
Soft callus formed by chondrocytes and fibroblasts[126]. The chondrocytes are dif-
ferentiated from mesenchymal progenitors and they replace the hematoma at the 
fracture site with cartilage[126]. Fibroblasts replace the deficient cartilage produc-
tion region with fibrous tissue. This produces a central fibrocartilaginous bridge 
between the fractured bone (Figure 1.2b). This semi-rigid cartilaginous callus pro-
vides some mechanical support to the fracture. Under the stimulation of vascular 
endothelial growth factor (VEGF), vascular endothelial cells would invade the soft 
callus and ingrowth of blood vessels[126]. This infiltration of blood vessel is impor-
tant for the mineralization of the callus[24, 56] 
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1.2.3 Hard Callus Formation 
The soft callus is removed gradually by chondroclasts and the hard callus is formed 
by osteoblast (Figure 1.2c){126]. The hard callus initially contains woven bone, 
which is nearly identical to the secondary spongiosa of the growth plate[33]. This 
process of formation of bone from a cartilage template is known as endochondral 
bone formation[33, 126]. Hard callus can form in the absence of soft callus. This 
process is known as intramembranous bone formation and often occur in fracture 
with high mechanical stability or adjacent to fracture site and an existing bone 
surface[33, 126]. Hard callus formation involves responses in the periosteum and 
external soft tissues. Delay of healing can be caused by damaged periosteum because 
the periostem is rich in stem cells[33, 126]. 
1.2.4 Bone Remodel ing 
Bone remodeling, the last stage of a traditional four stages fracture healing, is a 
coupled process of bone resorption and formation which replaces woven bone with 
lamellar bone and restores the standard cortical structure (Figure L2d)[126, 130， 
88, 85, 125]. The key cell type for bone remodeling and resorption of mineralized 
bone is osteoclasts. Osteoclast replaces the less mechanical support woven bone 
with high mechanical strength laminar bone in bone remodeling[125]. 
1.3 Low Magn i tude High Frequency Vibra t ion (LMHFV) 
St imulat ion 
Vibration is a form of oscillation. The magnitude of a sinusoidal vibration can be 
expressed as the displacement from the neutral point with the equation 
M( t ) - A x sin(27rft + 0) 
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Figure 1.2: Four stages of fracture healing, a: Inflammation and hematoma formation, 
b: Soft callus formation, c: Hard callus formation, d: Bone remodeling. (Reprinted from 




















































































































































































































































































































































































































































































































CHAPTER 1. INTRODUCTION 10 
The maximal displacement from the neutral point is defined as the amplitude (A). 
The number of cycles of the wave in a unit of time is called the frequency ( / ) . From 
this equation, the acceleration from the vibration, in terms of the gravitational force 
of the earth, can be calculated by the equation 
= M27rfy 
9 ~ 9.81 
From the frequency of the wave ( / ) and the duration of the treatment, the number of 
loading cycles can be calculated as Loading Cycle = Frequency x Duration of Treatment. 
Furthermore, the frequency or strain rate is important to determine the response 
of bone to the mechanical stimulation. This is because the strain threshold required 
to maintain bone mass follows a nonlinear function of loading cycle number (Figure 
1.4)[108]. This suggested that the total amount of strain required to maintain bone 
mass depends on the total number of loading cycle. As mentioned previously, num-
ber of loading cycle is the product of frequency of the waveform and the duration 
of treatment. 
1.3.1 Mechanical Stimulation 
WolfF's Law 
In 1892, Wolff stated that mechanics can change the architecture of bone[45]. The 
Wolff's law states that 
Every change in the form and function of bone or of their function alone 
is followed by certain definite changes in their internal architecture, and 
equally definite alteration in their external conformation, in accordance 
with mathematical laws. 
Even though the Wolff's law predicts that there is changes in bone architecture after 
mechanical loading, however it does not state the mechanism on how this change 
occurs[45]. 
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Figure 1.4: There is a nonlinear relationship between stain threshold and number of 
loading cycle. As the number of cycles increases, the strain required to maintain bone 
mass decreases. However, the changes are not proportional to each other. (Reprinted 
from Qin et al. 1998)[108] 
Mechanostat Theory 
The mechaostat theory (MST) is proposed by Frost[47, 46，136]. MST states that 
weight-bearing bones are genetically equipped with physiological signal threshold for 
maximal and minimal strains. Mechanical strain is a function of load-bearing[117]. 
During passive activities such as standing, muscle would generate less than 5 micros-
train in amplitude with a frequency of 10 — 50 Hz[44]. The bone mass is regulated by 
bone strains via feedback mechanism which is analogous to the temperature regula-
tion by a thermostat[136]. Therefore, when the upper limit of bone stain is reached, 
there would be a net bone synthesis. However, when bone stain reaches the lower 
threshold, there would be a net bone resorption (Figure 1.5)[136]. The mechanical 
loading between these two thresholds would have no net change of net bone mass. 
Under different physiological conditions, the threshold values might change in 
order to stimulate bone formation or bone resorption[136]. In osteoporosis, cal-
cium and estrogen depletion might shift the thresholds to the right. Therefore, 
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higher mechanical load would be needed to stimulate bone formation. Microfrac-
tures might lower the thresholds so less mechanical loading is needed to stimulate 
bone formation[136]. 
J ^ Bonc dainagc. 
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Figure 1.5: The mechanostat theory proposed by Frost[45, 136]. When mechanical loading 
of the bone reaches the upper threshold, there would be a net bone synthesis. On the 
other hand, when bone is disused and mechanical loading reaches the lower threshold, 
there would be a net bone resorption. However, when there is excessive loading and bone 
stain reaches the pathological threshold, the bone would be damaged. (Reprined from 
Frost 1994)[45] 
1.3.2 Effect of L M H F V on Bone 
Low-magnitude High-Frequency Vibration (LMHFV) is a form of systemic, nonin-
vasive, and cyclic biophysical stimulation. Vibration has potential effects on phys-
iological systems and the potential interplay among systems. Vibration modulates 
skeletal, muscular, endocrine, nervous, and vascular systems. Rubin et al. reported 
that adult sheep that stand on a vibration platform for 20 min/day for 5 days a 
week over one year had increased femoral trabecular bone density by 32%[117]. Gusi 
et al. reported that postmenopausal women treated with vibration had increased 
bone mineral density by 4.3% compared to walking[54]. Xie et al. reported that 
vibration can inhibit trabecular bone resorption in growing skeleton which might 
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increase peak bone mass non-pharmacologically[142]. 
LMHFV effect on Fracture Healing 
LMHFV not only have an effect on intact bone, it also have an effect on fractured 
bone. In our previous study, LMHFV (0.3 g, 35 Hz) enhanced fracture healing in 
three month old non-osteoporotic Sprague-Dawley rats (SD rats), and nine month 
old ovariectomy (OVX)-induced osteoporotic and nomral adult rats[76, 129]. The 
three month old SD rats that were treated with LMHFV for four week and the rate of 
fracture healing was improved by 25-30%[76]. The rats under LMHFV stimulation 
had larger callus than sham rats (Figure L6)[76]. The healed fracture after 4 weeks 
of LMHFV had better mechanical strength (50.1% stronger than sham) with respect 
to ultimate load and stifFness[76]. This suggested acceleration of fracture healing. 
Furthermore, similar results were found in the nine month old rats. These rats were 
treated with LMHFV for eight weeks. LMHFV promoted fracture healing in OVX 
group in all callus measurements especially in the early phases of healing[129]. Callus 
formation, mineralization and remodeling were enhanced by 25 - 30% compared to 
the OVX control. In addition, the energy to failure was enhanced by 70%[129]. 
In young, adult nonosteoporotic, and adult OVX-induced osteoporotic rats, the 
LMHFV treated rats had larger callus measurement in the middle of treatment 
period (Week 2 and week 4 for young and adult rats respectively) (Figure 1.6 and 
1.7). Moreover, at the end of treatment period (week 4 and week 8 for young 
and adult rats respectively), the LMHFV stimulated rats had comparable callus 
measurement to their respective control rats. From this observation in LMHFV 
rats, LMHFV might not only enhance the early phases of fracture healing but also 
the later bone remodeling phase. The rate of disappearance of callus seems to be 
faster in LMHFV treated rats than sham. This effect suggested that the later phase 
of fracture healing might be influenced by LMHFV. 
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Figure 1.6: Callus area and width in three month old rats. (Reprinted from Leung et al. 
2009)[76] 
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Figure 1.7: Callus area and width in nine-month old OVX-induced osteoporotic and nonos-
teoporotic rats. (Reprinted from Shi et al. 2010)[129] 
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1.4 Osteoporosis and Osteoporot ic F rac tu res 
Osteoporosis 
Osteoporosis means porous bone. According to the World Health Organization 
(WHO), osteoporosis is defined as: 
a systemic skeletal disorder characterized by low bone mass and microar-
chitectural deterioration of bone tissue, with a subsequent increase in 
bone fragility and susceptibility to fracture[7]. 
The first Consensus Conference on Osteoporosis of the new millennium proposal a 
new definition of osteoporosis as: 
a skeletal disorder characterized by compromised bone strength predis-
posing to an increased risk of fracture[7]. 
Osteoporosis is diagnosed by measuring the bone mineral density (BMD) using dual 
X-ray absorptiometry (DXA). When BMD is more than 2.5 standard deviation 
below the sex-matched young adult mean, this would be classified as "established 
osteoporosis" [7, 57]. On the other hand, osteopenia, which defined as low bone 
mass, was set at BMD is between 1.0-2.5 standard deviation lower than average[7]. 
Osteoporotic Fracture 
Osteoporotic fractures affect women more than heart attacks, strokes, and cancers 
that occur in female only combined[7]. Vertebral, distal forearm, and hip fracture 
incidence increases exponentially with age (Figure 1.8)[57]. Therefore, osteoporotic 
fractures at these locations are regarded as typical[124]. In addition, risk of frac-
ture increases in patients who had any type of fragility fracture previously[116]. 
A vertebral fracture would increase the risk of a subsequent vertebral fractures by 
10-folds[124]. 
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1.4.1 Epidemiology of Osteoporot ic Fracture 
Osteoporosis is a major health problem. Osteoporosis is identified as one of the 
most important diseases, along with hypertension and diabetes mellitus, that is 
affecting the human[7]. Each year, approximately 200 million people are at risk of 
an osteoporotic fracture and 40% of women and 14% of men over 50 years of age 
will experience fractures related to osteoporosis[30]. In 2000, it was estimated that 
there was 424,000 and 1,098,000 hip fractures in men and women respectively[50]. 
As life expectancy increases, there would be 800,000 and 1.8 million hip fractures 
by the year of 2025 in men and women respectively[50], In 1990, the direct and 
Indirect cost of hip fracture costed about $34.8 billion USD annually[5T]. In 1997, 
the annual cost reached $131.5 billion USD[124]. The cost is expected to increase 
substantially and globally over the next 50 years with the aging population[57]. 
In Hong Kong, a cross-section study found women over 60 and women over 70 
years old had lower mean bone mass than young healthy women by 30% and 50% 
respectively[59]. Therefore, prevalence of osteoporosis in Hong Kong would also 
increase substantially with aging population. The current trend suggested that in 
2015, 5293 women and 2349 men would have a hip fracture[61]. 
1.4.2 Pathophysiology 
Bone strength is contributed by many skeletal characteristics and bone qualities[124, 
135]. These include macroarchitecture of bone (shape and geometry), microarchitec-
ture of both cortical and trabecular bone, matrix and mineral composition, degree 
of mineralization, microdamage accumulation, and the rate of bone remodeling and 
turnover[124, 135]. As mentioned in section 1.4, osteoporosis is a skeletal disorder 
characterized by low bone mass and microarchitectural deterioration of bone tissue. 
These morphological changes lead to increase in bone fragility and increase incidence 
of fracture. 
In postmenopausal women, bone mass decreases due to decrease in estrogen pro-
duction and other age-related mechanisms such as secondary hyperparathyroidism 
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Figure 1.8: Exponential increase of fracture incidence at hip, wrist and vertebra with age 
in males and females. (Reprinted from Sambrook et al. 2006)[124] 
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and reduced mechanical loading[124]. Skeleton is continually remodeled by a coupled 
activity of bone formation and bone resorption. This coupled activity is not balance 
in postmenopausal osteoporosis. Due to aging, osteoblasts become dysfunction[37]. 
Therefore, the activity of osteoblast and osteoclast is not balanced. In addition, 
the rate of bone remodeling is increased. This would magnify the decrease in bone 
mass caused by the imbalance of bone remodeling[124]. This would also lead to a 
progressive loss of trabecular bone due to increased osteoclastogenesis[124]. 
Estrogen exerts anti-resorptive effects on bone at a cellular level. The receptor 
activator of NF^B ligand (RANKL) is a signaling molecule for osteoclast differen-
tiation and increased bone resorption. Normally, RANKL binding on osteoclast is 
blocked by osteoprotegerin protein (OPG). Estrogen stimulates the production of 
OPG in osteoblast. Estrogen deficiency in postmenopausal women caused an up 
regulation of RANKL and down regulation of OPG. Therefore, this would enhance 
the osteoclast activity and survival would leads to increase bone resorption. 
Menopause is associated with decrease calcium absorption and increase calcium 
excretion which would lead to calcium imbalance[98]. Calcium absorption falls with 
age due to decline in gastrointestinal sensitivity to calcitriol, also known as 1,25-
dihydroxycholecalciferol. This molecule is responsible for dietary calcium absorption 
(Figure 1.9)[48, 98]. The increased calcium excretion is probably due to increase in 
bone resorption in menopause and reduction of calcium reabsorption in the tubular 
of the kidney[98j. Therefore, the serum calcium concentration and bone calcium 
content would decrease even further. Estrogen enhances intestinal absorption ef-
ficiency and improves renal calcium conservation[58]. Therefore, postmenopausal 
women might have lower serum calcium concentration due to estrogen deficiency. 
Under low calcium condition, the body would secret parathyroid hormone (PTH)(Figure 
1.9)[131]. PTH is a hormone that is secreted by the parathyroid glands[48]. PTH 
increases bone resorption and mobilize C a 2 + . This is a compensatory mechanism 
by the body to increase calcium concentration. This increase in secretion of PTH 
would cause secondary hyperparathyroidism. In addition, estrogen seems to have a 
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direct depressive action on the parathyroid gland while estrogen deficiency increases 
the sensitivity of bone to PTH[131]. Therefore, the increased sensitivity of bone to 
PTH and increased secretion of PTH would further decrease the mineral content in 
bone in people with postmenopausal osteoporosis. 
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Figure 1.9: Impaired calcium balance in postmenopausal osteoporosis. The body increases 
secretion of P T H and production of 1,25-dihydroxycholecalciferol to compensate the lost 
of calcium. However, aging lead to impaired kidney function and cause excess urinary 
excretion of calcium. (Modified from Ganong et al. 2009[48]) 
1.4.3 Osteoporotic Fracture Healing 
Under osteoporotic conditions, the fracture process of bone is delayed even though 
it goes through all the normal stages[50, 97]. Factors which may contribute to the 
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delay healing in osteoporotic patients are decreased bone mechanical stability[23], 
impaired angiogenesis[110], reduced osteoblastic activity to signaling molecules[96], 
and deficiencies of mesenchymal stem cells[16]. In our previous study, there is a 
reduction of callus area and width, and mechanical strength in the femoral fracture 
of osteoporotic rats compared to normal rats[129]. Clinically, increase in the rate of 
failure of implant fixation in osteoporotic patients was observed[6]. 
Management of Osteoporotic Fracture 
For treating osteoporotic fractures, there are three factors that the surgeon would 
consider (Figure 1.10). The three factors are the quality of the soft tissue surround-
ing the fracture site, the fracture pattern, and the patient[50]. For soft tissue quality, 
the elderly might have thin skin due to atrophy or malnutrition would be suscepti-
ble to degloving injuries[50].0ther soft tissue problems found in the elderly include 
arterial diseases such as venous hypertension, and ulcers[50]. The fracture pattern 
for the elderly are often complex because of the changes in mechanical properties of 
bone. The elderly often has medical comorbidities which would have a major impact 
on the patient factor for treatment options[50]. 
The operative treatment for osteoporotic fracture is a challenge for surgeons 
because the outcome is often unpredictable. Since there is endosteal diaphyseal 
resorption and medullary expansion in osteoporotic bone, the bending and torsional 
characteristics of the entire bone would be changed. In addition, the holding capacity 
of the screws might also be affected due to the decreased density in cortical bone[50]. 
Osteoporotic Fracture Model 
Osteoporotic fracture model was used in order to study the effect of LMHFV on bone 
remodeling in fracture healing. Osteoporosis delays fracture healing even though 
healing goes through all the normal stages. The advantage of using this fracture 
model is that the prolonged fracture healing which would allow detailed observation 
of each healing stage. Therefore, the subtle changes within the fracture callus can 
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Figure 1.10: An algorithm for the management of osteoporotic fracture. (Reprinted from 
Giannoudis et al. 2006)[50]. 
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be observed and studied. 
1.5 B i sphosphona te 
Bisphosphonate is a anti-catabolic agent which is used for osteoporosis. It is taken 
up by osteoclast during resorption at active remodeling sites. Uptake of bisphos-
phonate by osteoclasts causes osteoclast apoptosis and leads to inhibition of bone 
remodeling[103, 121, 130]. 
1.5.1 Background 
Bisphosphonate is an effective inhibitor of bone resorption for the treatment and 
prevention of osteoporosis[112]. Depending on the specific bisphosphonate, the risk 
of hip and vertebral fractures was reduced by 40 — 60% (Table 1.1)[1, 112], Bis-
phosphonates decrease rate of bone remodeling into premenopausal range, maintain 
trabecular and cortical microarchitecture, reduce cortical porosity, and improve bone 
mineralization[19, 38, 113]. 
Table 1.1: Reduction of vertebral fracture risk by alendronate, risedronate, and iban-
dronate with daily or intermittent regimen (Source: Adami 2007)[1]. 
Fracture Risk Reduction Bisphoshonate 
Vertebral Fracture Non-vertebral Fracture 
Alendronate [10 mg/day] 47% 36% 
Risedronate [5 mg/day] 49% 39% 
Ibandronate [2.5 mg/day] 62% 69% 
Bisphosphonates are analogs of pyrophosphate which has a high affinity for cal-
cium crystals[103]. Bisphosphonates have a backbone structure of (P-C—P), which 
is similar to the backbone structure of pyrophosphate (P-0-P)[112]. This back-
bone structure makes bisphosphonates resistant to biological degradation[102, 103]. 
Therefore bisphosphonate are excreted unmetabolized in urine[102, 103]. 
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This P—C—P structure allows bisphosphonate to bind to the divalent metal ions, 
such as C a 2 + , on bone surfaces[27]. This high affinity to bone surface allow bispho-
sphonate to have a highly selective effect on osteoclast. 
Bisphosphonate is different from pyrophosphates that it has two extra side chains, 
R x and 2 , attached to the central carbon atom. Most of the common bisphos-
phonates, except clodronate, have a hydroxyl group (—OH) at Ri. This enhances 
the affinity of bisphosphonate to calcium crystals on the bone surface. However, 
different bisphosphonate have significantly different kinetic binding affinities for 
hydroxylapatite[94]. These differences in kinetic of binding are attributed to dif-
ferences in the R2 side chain[94]. R2 side chain can influence the bone affinity as a 
result of the ability of nitrogen moiety to bind to the bone surface. The N-BP that 
has a larger R2 side chain is more potent[94]. 
1.5.2 Mechanism of Act ion 
Bisphosphonate is preferentially deposited at sites, such as fracture callus and active 
remodeling sites, where minerals are exposed by osteoclast[77, 103, 112]. There 
are two groups of bisphosphonates: nitrogen-containing (N-BP) and non-nitrogen-
containing[121]. These are referred to whether the R2 side chain contains a nitrogen 
atom[103]. 
The N-BP, such as alendronate, risedronate, ibandronate, and zoledronate, in-
terfere other metabolic reactions in osteoclasts[121]. This group of bisphospho-
nate interferes the mevalonate biosynthetic pathway and affects cellular activity, 
cell survival, and protein prenylation. The mevalonate pathway is responsible for 
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the production of cholesterol, other sterols, and isoprenoid lips such as isopen-
tenyl diphosphate, farnesyl diphosphonate (FPP) and geranylgeranyl diphosphoate 
(GGPP)[121]. F P P and GGPP are important for posttranslational modification 
and prenylation of small GTPases (Figure 1.11). N-BP has a mechanism of action 
is similar to statins, a drug known to target cholesterol pathway[41]. Both statin 
and N-BP inhibit osteoclast formation and osteoclastic bone resorption through 
inHibition of mevalonate pathway[112]. 
The non N-BP closely resemble pyrophosphate[121]. These non N-BP includes 
clodronate and etidronate. This group of bisphosphonate seem to act as prodrugs 
and converted to active metabolites after intracellular uptake by osteoclast[121]. 
These bisphosphonates are incorporated into nonhydrolzable analogues of adeno-
sine triphosphate (ATP) by reversing the reactions of aminoacyltransfer RNA syn-
thetases. This would create nonhydrolyzable metabolites that contain the P-C-P 
moiety in place of the ^,7-ph0sphate group of ATP (Figure 1.11). These metabo-
lites would accumulate within osteoclasts and inhibits their function. This may also 
cause osteoclast apoptosis[121]. 
1.5.3 Usage of Bisphosphonate 
As mentioned in section 1.5.1, bisphosphonate can decrease bone resorption. This 
effect of bisphosphonate allow it to be used in the management of conditions with 
excessive bone resorption which includes Paget's disease of bone and malignancy-
associated hypercalcemia[103]. Furthermore, bisphosphonate administrated system-
atically or to be coat on the screw. These administration of bisphosphonate would 
increase the screw removal resistance and integration[4, 72]. Another usage of bis-
phosphonate is on cancer patients. Many cancers are associated with bone destruc-
tion and hypercalcemia due to increase of PTH[119]. Bisphosphonates may have 
direct effect on the tumor cells such as induction of tumor cell apoptosis[25]. 
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Figure 1.11: Mechanism of action of non-nitrogen-containing and nitrogen-containing bis-
phosphonate on osteoclast[121, 122]. Non-nitrogen-containing bisphosphonate incorpo-
rates into ATP and form non-hydrolyzable metabolite. Nitrogen-containing bisphospho-
nate inhibits prenylation of GTPasse in the mevalonate pathway. (Reprinted from Russell 
et al. 2009)[122] 
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1.5.4 Bisphosphonate Effects on Fracture Heal ing 
Even though bisphosphonates reduce fracture risks significantly, there are issues 
with the use of bisphosphonate. Bisphosphonate remains in the skeleton for very 
long time due to their long half life (200 days for alendronate)[80]. The physiological 
effect of these bisphosphonate is still unknown. Bone turnover markers remained 
suppressed after discontinuation of bisphosphonate[34]. Suppression of bone remod-
eling would impair the repair ability of bone and lead to accumlation of microdam-
ages in bone[86]. A large amount of bisphosphonate with low inhibitory efficacy, 
such as etidronate, would produce a mechanically weaker fracture callus[T4]. In ad-
dition, administration of bisphosphonate during fracture healing might delay bone 
remodeling[90, 100].Furthermore, long-term usage of high dosage bisphosphonate 
might lead to atypical fracture of the femoral shaft[3, 9, 10, 51, 40，124]. 
1.6 Hypothes i s 
As mentioned in section 1.3.2, our previous studies showed LMHFV (35 Hz, 0.3g 
peak-to-peak acceleration) enhanced callus formation, mineralization and fracture 
healing in both adult rats[76] and aged osteoporotic rats[129]. The mechanical 
strength of the healed fracture at the end of treatment was also improved[76, 129]. 
Furthermore, an increased rate of disappearance of callus in terms of callus area 
and width was observed in these studies. This observation suggested that LMHFV 
enhanced bone remodeling in fracture healing. However, more information is needed 
to verify this enhancement of bone remodeling and the mechanism of action of 
LMHFV on fracture healing was still not well understood. Our hypothesis was 
that L M H F V enhanced bone remodeling in fracture healing. 
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1.7 S t u d y P l a n 
To verify our hypothesis, nine month old female OVX-induced osteoporotic rats were 
undergone closed-fracture surgery. LMHFV stimulation was applied on these rats. 
In addition, LMHFV-stimulated bone remodeling was suppressed by the adminis-
tration of ibandronate (Bis), a nitrogen-containing bisphosphonate[ 121, 120]. The 
changes in both remodeling by LMHFV in the presence and absence of ibandronate 
would be investigated. 
1.7.1 Object ives 
The objectives of this study are listed as follows: 
1. To study the effect of LMHFV on bone remodeling in fracture healing in the 
presence or absence of bisphosphonate with respect to radiological, microar-
chitectural, histomorphometric, and biochemical analyses. 
2. To study the effect of LMHFV on bone resorption during fracture healing with 
respect to biochemical analysis. 
3. To study the effect of LMHFV on bone formation during fracture healing with 




2.1 Ovariectomized R a t Femoral F rac tu re Model 
In this study, osteoporotic rats were used in this study. The female retired breeders 
of Sprague-Dawley (SD) rats were obtained from the Laboratory Animal Services 
Center (LASEC) of the Chinese University of Hong Kong (CUHK). The rats were 
housed and acclimatized at the laboratory of research animals of the Prince of Wales 
Hospital. The rats were housed in a 12-hour light-night cycle room. The rats were 
allowed with free cage movements and had ad libitum access to standard rat diet and 
tap water. The Chinese University of Hong Kong Animal Experimental Ethics Com-
mittee approved the experimental protocols of this study (Ref. No. 08/024/MIS). 
2.1.1 Ovariectomized Rat Model 
Osteoporotic rat were developed according to our previously established protocol[129]. 
Bilateral ovariectomies (OVX) were performed on six-month old female SD rats. The 
rats were then allowed three months for the development of osteoporosis. 
Six-month old female SD rats («250 grams, retired breeders) were obtained from 
LASEC of CUHK. General anaesthesia (Ketamine (75 mg/kg) and Xylazine (10 
mg/kg) mixture, i.p.)[128] was given to the rat. After the rat was anaesthetized, 
the hair on both sides of the rat was shaved from the lower rib to the top of the 
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thigh. The dimension of the area that the hair of the rat was shaved was approx-
imately 4 x 4 cm. The region that the hair was shaved on the rat was sterilized 
with 0.5% Hibitane in 70% ethanol. Then the rat was positioned laterally. The 
ovariectomy was performed with bilateral ovaries approached (Figure.2.1). An in-
cision of 8 mm was made between the lowest rib and the top of the thigh. The 
abdominal wall was dissected using a pair of scissors and an incision of 1 cm was 
made. After dissection of the lateral abdominal wall, the ovaries were explored in the 
abdominal cavity and exposed (Figure 2.1b). Then the ovary, part of the oviduct, 
concomitant vessel and some visceral fat were ligated (3-0 sutures, Mersilk, Ethicon 
Ltd., Belgium) and resected. The abdominal wall and the skin were then sutured in 
layers by interrupted suture (3-0 sutures). After the removal of the ovary was com-
pleted on one side, the rat was turned to the other side and the surgical procedures 
were repeated. Buprenorphine (0.03 mg/kg, subcutaneous injection (sc), Temgesic, 
Schering-Plough, NJ, USA) was given for analgesia after both ovaries were removed. 
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(a) Surgical Position and location of incision (b) Exposed Ovary 
Figure 2.1: The surgical procedure of bilateral ovariectomy, a: Lateral incision to ap-
proach bilateral ovaries. The red circle shows the location of incision, b: Exposed ovary 
surrounded by visceral fat. 
CHAPTER 2. METHOD 31 
2.1.2 Closed Femoral Fracture 
After OVX was performed on the six month old rats, the rats were waited for three 
month to develop osteoporosis. When the osteoporotic rats were nine month old, 
closed femoral fracture was performed on the right femur of the rats according to our 
established protocol[76, 129]. This surgical procedure was modified from the closed 
femoral fracture surgery that was developed by Einhorn et aL[ll]. All surgical 
equipments were autoclaved one day before the surgery. All surgical procedures 
were performed by a single experienced technician in order to keep the quality of 
the surgery consistent. After general anaesthesia was admirxstrated to the rat, the 
rat was placed on the surgical table supinely. The hair on the right hinder limb was 
shaved and prepared with aseptic techniques (0.5% Hibitane in 70% ethanol). A 
10 mm incision was made on the medial side of the limb and 2 mm medial to the 
patella (parapatellar incision). The femoral condyle was exposed by dissection of 
joint capsule of the knee. The patella was laterally dislocated and the intercondylar 
notch was exposed (Figure 2.2a). The intercondylar notch was used as an entry point 
for reaming. Reaming was performed with an 18G needle (Figure 2.2b and 2.2c). A 
sterilized Kirschner wire (K-wire, 0 1.2 mm, Sanatmetal Ltd., Eger, Hungary) was 
inserted through the entry point into the medullary canal. The K-wire perforated at 
the proximal femur. The end of the K-wire at the proximal femur was bended into a 
hook to prevent distal movement. The K-wire at the femoral condyle was cut at the 
level of the articular surface at the distal femur to ensure smooth joint movements. 
The patella was relocated onto the articular surface with joint capsule. The skin 
was stitched discontinuously (3-0 sutures, Mersilk, Ethicon Ltd., Belgium). 
After the intramedullary pin was inserted, the rat was positioned on a cus-
tomized 3-point-bending apparatus (Figure 2.3a) which was used in our previous 
studies[76, 129]. A transverse fracture was created in the midshaft (diaphysis) of 
the right femur by dropping a metal blade (« 500 g) from a height of 35 cm. The 
fracture was confirmed by anteroposterior and lateral radiographs (Radiological pro-
tocol in section 2.6.1). The rats with comminuted fracture were excluded from the 
CHAPTER 2. METHOD 32 
experiment. Buprenorphi^e (0.03 mg/kg sc. Temgesic, Schering-Plough, NJ, USA) 
was given 15 min pre-operation, and one day post-operation for analgesics. 
2.2 S t u d y Design 
Eighty osteoporotic and femoral fractured rats were randomly divided into four 
groups: control (CG) , LMFHV group (VG) (See Section 2.3 for details), bisphos-
phonate group (BG) (See section 2.4 for details), and both LMFHV and bisphospho-
nate treated group (VBG) . In each treatment group, the rats underwent treatment 
for one of the four durations: 2，4，6, or 8 weeks. All treatments were started five 
days post-fracture to ensure full weight bearing on the fractured femur[76, 129] . Lat-
eral x-rays (Faxitron X-ray system model 43855C, Wheeling, IL) were taken weekly 
(3 sec exposure time with a tube voltage of 60 kVp) in order to monitor the fracture 
healing status (See section 2.6.1 for details). At the end of treatment, the rats were 
anaesthetized and blood was collected by cardiac puncture. After blood collection, 
the rats were euthanized using overdose of sodium pentobarbital and the fractured 
femora were collected for ^ C T analysis. 
2.3 L M H F V Trea tmen t Pro toco l 
In this study, the vertical LMHFV was created by a customized magnetic levitation 
vibration platform which was developed and used in our previous studies[76, 129] 
(US patent pending). Since the platform was initially designed for human subjects, 
modification of the vibration platform was made to allow to be used for animals. 
An aluminum platform, which was custom-made to the dimension of the vibration 
platform by the Mechanical Service Unit in CUHK, was placed on top of the vi-
bration platform. Two pieces of plastic foam (2.5 cm thick for each) were placed 
between the aluminum platform and two 25 kg mass (Figure 2.4a). A plastic plate 
and a aluminum plate was placed between and on top of the plastic foam respec-
tively. This setup would ensure the weight of the two 25kg mass was distributed 
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(a) Medial parapatellar incision (b) Intercondylar notch 
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(c) Intramedullary drilling and reaming (d) K-wire Insertion 
Figure 2.2: Surgical procedures for intramedullary pinning, a: Medial parapatellar incision 
and articular surface of the femoral condyle, b: Intercondylar notch was exposed by lateral 
dislocation of the patella, c: Intramedullary drilling and reaming with an 18G needle, d: 
The tip of the K-wire was bended to prevent distal migration. 
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(a) Three-point-bending apparatus (b) Right femoral fracture on rat 
Figure 2.3: Closed femoral fracture procedure and apparatus, a: Three-point-bending 
apparatus used to create closed femoral fracture, b: The blade was dropped onto the 
midshaft of the right femur after the intramedullary pin was inserted. 
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evenly over the vibration platform and eliminated the need to remove the weights 
after completion of each treatment. This would reduce the variation of wave form 
between treatments (Figure 2.4b). 
A plastic sheet was placed under the bottomless and compartmented cage to 
transfer the rats onto the vibration platform (Figure 2.4a). The cage with the 
plastic sheet was slid into position on the vibration platform. The plastic sheet was 
slid out under the cage while keeping minimal disturbance to the rats. This allowed 
the rats to stand on top of the vibration platform and the vibration stimulation 
would transfer to the rat through their feet directly (Figure 2.4c). The duration of 
treatment was electronically controlled by a timer. After 20 min of treatment, the 
rats were transferred back to their cages. 
The rats in VG and VBG stood separately in a bottomless, compartmented cage 
on the vibration platform for 20 min/day, 5 days/week[76, 129]. The black partitions 
were used to prevent the rats from disturbing each other. This was necessary to 
stablilize animal behaviors. The vibration platform provided vertical low-magnitude 
high-frequency vibrations at 35 Hz with a peak-to-peak acceleration of 0.3g (g = 
gravitational acceleration), which were the same parameters that were used in our 
previous studies[76, 129]. The rats in CG and BG stood on the unpowered vibration 
platform in order to receive sham treatment with same regime. 
2.4 Bisphosphonate Trea tmen t Pro tocol 
2.4.1 Pharmacological Parameters 
There are a few commonly used bisphosphonates available in the market including al-
endronate (Fosamax@), ibandronate (Boniva@), and risedronate (Actonel@)[91]. 
Ibandronate was chosen for bisphosphonate treatment due to its high efficacy com-
pared to other available bisphosphonates. The pharmacokinetics of ibandronate are 
studied preclinically[93, 5]. 
The optimal ibandronate dosage to prevent bone lost was determined to be 1 
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(b) LMHFV wave form (c) Rats in bottomless cage 
Figure 2.4: LMHFV procedure and setup, a: An aluminum platform is placed on top of 
the LMHFV platform. Two pieces of plastic foam are placed between the two 25 kg weights 
and the aluminum platform. A plastic plate and a aluminum plate was placed between 
and on top of the plastic foam respectively. The bottomless cage is placed under the 
aluminum platform. The piece of plastic is removed during treatment, b: The waveform 
of LMHFV measured by a oscilloscope. The waveform was sinusoidal, c: The rats stand 
inside the bottomless cage individually while the hind legs stand on the platform directly. 
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pg/kg/day in OVX rats[8, 120]. The frequency of administration for bisphosphonate 
would not affect the efficacy of the drug[8]. The effect of bisphosphonate depends 
on the total administered dose in a given period[8, 120]. The bioavailability does 
not vary significantly between different routes of administration other than oral, 
which has bioavailability of <l%[5, 39, 80]. In addition, subcutaneous injection 
showed comparable bone concentration to intravenous injections[80]. Therefore, 
weekly subcutaneous injection of ibandronate (1 yUg/kg/day) was administered for 
the optimal anti-resorptive effect. For CG and VG, saline was injected weekly for 
sham ibandronate treatment. 
2.4.2 Ibandronate Injection Solution Preparation 
1.4 mg of ibandronate sodium (Sigma Chemical Ltd., St. Louis, MO, USA) was 
dissolved in 200 mL of 0.9% saline to make an ibandronate injection solution (7 
^g/mL). The ibandronate solution was stored at 4 � C until injection. Before injec-
tions, the ibandronate solution was equilibrated at room temperature. 
2.4.3 Injection 
General anesthesia (Ketamine (75 mg/kg) and Xylazine (10 mg/kg) mixture, i.p.) 
was given to the rats before ibandronate injection. The rat was weighted on a 
spring balance before each injection to ensure the injected dosage of ibandronate was 
accurate and consistent. The equation for calculating the dose and the corresponding 
volume of injection is 
Dosage [mg/kg] x mass [kg] 二 Dose [mg] 二 Solution Concentration [mg/mL] x Volume [mL] 
(2.1) 
For subcutaneous injection, the rat was put into supine position. The back skin of 
the rat was gently raised. A 25G needle was inserted at a shallow angle and parallel 
to the back of the rat. Ibandronate solution (7 pg/mL) was injected subcutaneously 
on the dorsal side of the rat. 
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2.5 F luorochrome Label ing 
2.5.1 Fluorochrome Preparat ion 
Calcein green (Sigma, Deisenhoren, Germany) and xylenol orange (Sigma, Deisen-
horen, Germany) fluorochrome injection solutions were prepared according to our 
previous established protocol[T5]. Calcein green and xylenol orange (0.5 g and 9 g 
respectively) were dissolved in 100 mL of distilled water to make up a concentra-
tion of 5 mg/mL and 90 mg/mL of calcein green and xylenol orange respectively. 
The pH of the solutions were adjusted to 7.2 with sodium hydroxide solution. The 
fluorochrome solutions were filtered and kept at room temperature and in dark. 
2.5.2 Injection 
General anesthesia (Ketamine (75 mg/kg) and Xylazine (10 mg/kg) mixture, i.p.) 
was given to the rats before fluorochrome injection. The fluorochromes were injected 
subcutaneously on the dorsal side of the rat. Calcein green and xylenol orange were 
injected at different time during treatment period. Calcein green (5 mg/kg) was 
injected two-weeks before euthanasia while xylenol orange (90 mg/kg) was injected 
one-week before. All the rats were weighted before each injection. The volume 
of injection was calculated by dividing the dosage of fluorochrome by mass of the 
rat. For fluorochrome injections, the value for dosage and concentration of solution 
were the same. From equation 2.1, the volume [mL] of injection is equal to mass 
[kg] of the rat. The fluorochrome was injected subcutaneously. A similar injection 
technique for administration of ibandronate was used for injection of fluorochrome 
(Section 2.4.3). 
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2.6 Assessments 
2.6.1 Radiographic Analysis 
Making of Radiographs 
The radiographs were taken according to our established protocols[76, 129]. General 
anesthesia (Ketamine (75 mg/kg) and Xylazine (10 mg/kg) mixture, i.p.) was given 
to the rats before x-rays were taken. The radiographs were taken with an x-ray 
machine for small animals (Faxitron X-ray Corporation, Wheeling, IL. USA). The 
exposure time was set as three seconds with and tube voltage of 60kVp. For the 
lateral x-ray, the rat was placed in prone position with the hip joints in abduction 
and 1350 of flexion (Figure 2.5a). The knee joints were flexed. For anterior-posterior 
(AP) radiographs, the rat was placed in supine position and the hip joints were fixed 
in adduction, extension, and 0� ro ta t ion . The distance between the x-ray source and 
the rat was kept at 40 cm. The X-ray films (18 x 24 cm X-Ray Film, Fujifilm Corpo-
ration, Tokyo, Japan) were developed by an automated developer (Optimax X-Ray 
Film Processor, Protec GmbH & Co. KG, Oberstenfeld, Ludwigsburg, Germany). 
The developed film was scanned (16 bit gray scale, 300 dpi, JPEG format) by a 
scanner (Epson Perfection 4990 Photo scanner, Epson Hong Kong Ltd., Wanchai, 
Hong Kong). 
Radiographic Measurements 
The radiographs were analyzed according to our established protocol[76, 129]. Two 
experienced orthopedic surgeons, who were blinded from the time point and group-
ings of the digital x-ray, graded the fracture healing status for each rat according 
to our previous protocols[76, 129]. Radiographic healing was defined as complete 
bridging of all four cortices of a mineralized callus[129]. Callus width (CW) is de-
fined as the maximum width of callus minus the outer diameter of femur (Figure 
2.5b). Callus area (CA) is equal to the size of radiopaque area of callus (Figure 
2.5c). Both CW and CA were measured on lateral x-rays of each rat by using Meta-
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morph Image Analysis System (Universal Imaging Corporation, Downingtown, PA, 
USA) [7.6, 129]. Each callus measurement was repeated three times and the average 
was recorded. The average for each group was plotted in a line graph. 
2.6.2 f iCT Analys is 
The fracture femur was harvested after euthanasia and the K-wire was removed 
gently. Then the fracture femur was wrapped in gauze and fitted in the sample tube 
(0 16 mm) (Figure 2.6a) and scanned with micro-CT (^CT40, Scanco Medical, Brt-
tisellen, Switzerland) according to our established protocol[76, 129]. The scan range 
was set to be 7 mm (368 slides) and the fracture line was set in the middle of this 
range. The resolution was set to be 16 ^m per voxel and 1024 x 1024 pixels. Region 
of interest (ROI) was selected from 2D images with a standardized threshold (>165) 
as mineralized tissue according to established protocol[76, 129]. Three dimensional 
(3D) reconstruction of mineralized tissue was performed according to our established 
protocol[76, 129]. A low pass Gaussian filter (Sigma 二 1.2, Support 二 2) was used 
for 3D reconstruction. Different thresholds were used in order to distinguish old 
cortical bone, and low and high density mineralized tissue in the callus[43]. The 
low density (150 一 350) and high density (> 350) analysis were performed in order 
to distinguish woven bone from old cortical bone or laminar bone. 
Quantitative analysis used all 368 slides of the 2D images. Low and high density 
evaluations were performed separately. Morphometric parameters that were evalu-
ated were total tissue volume (TV), total bone volume (BV) , high- and low-density 
bone volume (BV^, and BV^ respectively) (where BV^ + BV^ = BV), and their re-
spective normalized BV with TV (BV/TV, BVh/TV, and BV Z /TV) were performed. 
The average for each group was recorded. 
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Figure 2.5: X-Ray analysis, a: Lateral X-ray was taken weekly to evaluate fracture healing 
status. A calibrator was placed next to the rat as a length reference, b: Callus width 
measurement (Di “ D2) on latera x-ray. c: Region of interest (Highlighted in green) for 
the analysis of callus area on latera x-ray. 
CHAPTER 2. METHOD 42 
•(邏國 ^ ^ ^ H t o X i 9 F _ 
y i w 
| ^ ^ g ^ H 
^ b i ^ p l B f l H H H ^ K ^ W ^ ^ ^ M ^ ^ M i M — H ^ ^ & ^ m i ^ 9 I I H I H H 
(a) fjiCT placement of sample ^ ^- — "^ .�-… — 一 —~~] 
D • i _ u ^ g g m ^ § — • 
(b) fj,CT 2D Contouring 
Figure 2.6: Micro-architecture analysis by ^CT. a: Placement of the sample in sample 
tube and ^ C T . b: 2D contouring of the region of interest (ROI). The region enclosed by 
the green line is the ROI. 
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2.6.3 Undecalc i f ied Histo logy 
M M A Sample Preparation 
Two weeks and one week before the euthanasia of the rats, calcein green (5 mg/kg) 
and xylenol orange (90 mg/kg) were injected respectively. The fluorochromes were 
purchased from Sigma (Deisenhoren, Germany). After scanning by ^,CT, the frac-
ture femora were dehydrated and prepared for undecalcified histomorphometry ac-
cording to established protocol[36, 75] . The excess muscle on the fractured bone 
was removed. The fracture femora were dehydrated serially in alcohol (70%, 95%, 
and 100%) and xylene, After dehydration was completed, the samples were embed-
ded in methylmethacrylate (MMA) (Table 2.1). The MMA solutions were prepared 
according to our established protocol[75]. 
Table 2.1: Tissue dehydration and embedding in methylmethacrylate for undecalcified 
histology. 
Reagent Day Per Change Sample inside Vacuum Storage Temperature 
Buffered Formalin 1 Day No Vacuum Room Temperature 
70% Ethanol 2 Days 1 hour/day Room Temperature 
95% Ethanol 2 Days 1 hour/day Room Temperature 
100% Ethanol 2 Days 1 hour/day Room Temperature 
Xylene 2 Days 4 hour/day Room Temperature 
MMA I 2 Days 4 hour/day 4°C 
MMA II 2 Days 4 hour/day 4°C 
MMA III 2 Days 4 hour/day 4 � C 
Note: All solutions were refreshed everyday. 
MMA solutions Preparation 
Water-free Methylmethacrylate (MMA) was prepared first. Washing solution was 
prepared by adding 200 grams of sodium chloride and 50 grams of sodium hydroxide 
in 1 L of distilled water. Then, 550 mL MMA (Merck Schuchardt OHG, Hohenbrunn, 
Germany) a,nd 300 mL washing solution were poured into the funnel. The funnel 
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with the MMA mixture was shook vigorously. Then, the funnel was placed on a 
stand and the mixture was allowed to separate. The lower layer was drained into 
a waste bottle. The upper layer was washed with washing solution for two more 
times and with distilled water for three times (For a total of six times). After the 
washing was completed, the upper layer was drained into a 1 L glass bottle with 60 
g of calcium chloride pellet (CaCl2) . The MMA was shook vigorously and stood for 
15 min for dehydration by CaCl 2 pellets. After the dehydration was completed, the 
CaCl 2 pellets were filtered by paper filters. The filtrate was the water-free MMA 
solution. MMA I, II, and III were prepared using different proportion of water-free 
MMA solution, butylmethacrylate, methylbenzoate, and benzoyl peroxide (Table. 
2.2). Benzoyl peroxide were dried by using desiccates for at least 3 days before 
addition to MMA. 
Table 2.2: Preparation of MMA solution I, II, and III. 
MMA I MMA II . 
Materials Volume [mL] Materials Amount 
Water-free MMA 500 MMA I 800 mL 
Butylmethacrylate 292 Benzoyl Peroxide 3.2 g 
Methylbenzoate 42 
Polyethylene glycol 400 10 
MMA III PMMA 
Materials Amount Materials Amount 
MMA I 800 mL MMA III 40 mL 
Benzoyl Peroxide 6.4g N,N-dimethyl-p-toluidine 160 fiL 
MMA Embedding and Sectioning 
After dehydration by serial alcohol and xylene, the samples were submerged in 
MMA solutions (Table. 2.1). Then, the sample was transferred to a vacuum for 4 
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hours. Afterwards, the sample was stored at 4°C. The MMA solutions were refreshed 
everyday and changed every 2-days. For polymerization, the sample was transferred 
to a 100 mL specimen cup. 20 mL of MMA III was added to the specimen cup and 
polymerized at -20 o C. Polymerization reaction of MMA was initialized by adding 
N,N-dimethyl-p-tolnidine to MMA III and spraying nitrogen gas the PMMA solution 
for 3 min. The specimen cup was half-opened by covering the cup with the lid. 
After spraying of nitrogen gas, the cup was covered, sealed, and stored at -20°C. 
By polymerizing 20 mL of MMA III solution, this created a smooth surface for 
embedding the sample. 40 mL freshly prepared MMA III was added to the sample. 
The sample was put in the vacuum for 4 hours. Then 160 ^L of N,N-dimethyl-p-
toluidine was added to MMA III and nitrogen gas was sprayed on the surface of the 
PMMA solution for 3 min. The specimen cup was half-opened by covering the cup 
with the lid. After spraying of nitrogen gas, the cup was covered, sealed, and stored 
at -20°C. 
After polymerization was completed, the fractured femur would be embedded in 
a yellow transparent solid MMA. The excess surrounding solid MMA were trimmed 
to make the base of sample parallel to the sagittal plane. The embedded sample 
was fixed on a custom-made holder using cyanoacrylate-based glue. The samples 
were sectioned sagittally (300 ^m thick) by saw microtome (Leica SP1600, Leica, 
Germany) using a circular saw which was 300 ^m thick. Excess water was used 
to minimize heating during sawing. Each section was polished and grinded to 100 
^im with different grades of sand paper before analysis. The polished samples were 
mounted on a plastic slide and were ready for analysis. 
MMA Analysis on Bone Mineralization Rate 
After preparing and grinding each slide to 100 ^m, the fluorochrome-label femur 
sections were observed under an ultraviolet fluorescent microscope (Leica DMRXA2, 
Leica, Germany). A digital picture was taken by the camera attachment on the 
microscope. The analysis was performed using Metamorph Image Analysis System 
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Figure 2.7: The procedure for embedding fracture femur in MMA. a: 20 mL of MMA 
was polymerized to provide a smooth surface for embedding of sample, b: Femur was 
embedded in polymerized MMA (total of 60 mL of MMA). c: Solid MMA was trimmed 
and grinded to be parallel to the cutting surface. 
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(Universal Imaging Corporation, Downingtown, PA, USA). Mineral apposition rate 
(MAR) was measured using standard histomorphometric procedure[109, 133]. MAR 
The region of interest for the MAR measurement was defined to be 2 mm to the 
proximal and distal to the fracture site. For each quarter of the callus that is 
within the region of interest, five points, which are 0.2 mm apart, on the distinct 
fluorochrome bands were chosen. If there were no distinct bands within the region of 
interest, the equal distance points were chosen at the lateral edge of the fluorochrome 
patch. The distance between the two fluorochromes was measured at these points. 
The average MAR was calculated to be the averages of the 20 measurements (5 
points/quarter, 4 quarters in the region of interest). MAR was measured from week 
4 - 8. The distance between the fluorochrome bands for 2 weeks treatment groups 
was not included because callus mineralization occurs during mid-second week post 
fracture (10 - 14 days post fracture) [33]. 
2.6.4 ELISA Analysis on Bone Markers 
Blood Sampling Procedure 
5 mL blood sample of the rat was collected via cardiac puncture under general 
anesthesia[28]. The rat was given general anesthesia and put in a dorsal position 
(Figure 2.8a). The heart was palpated by placing fingers on the side of the chest at 
the level of the rat 's elbows. The needle is directed into the heart at the place with 
the maximal heart beat. A 5 mL syringe with a 21G needle was used to puncture 
the heart from the left side laterally. When a flow of blood into the tip of the needle 
was observed, the syringe plunger was pulled back slowly to avoid hemolysis. After 
5 mL of blood was collected, the needle was removed from the syringe. The blood 
in the syringe was emptied into a 15 mL centrifuge tube. After collection of blood 
from the rat, overdose of sodium pentobarbital was administrated to make sure that 
the rat would be dead after exsanguination. 
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(b) Blood samples were stored in ice 
Figure 2.8: The blood sampling procedure, a: Lateral incision to puncture the heart 
with a syringe needle, b: Collected blood was stored in ice before separation of blood by 
certrifugation 
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Blood Serum Preparation 
The whole blood samples were kept in ice for one hour before separation by centrifu-
gation. The blood samples were centrifuged at 3000 rpm (^2000g) for 15 min. The 
blood semm was separated and aliquoted into 500 fjL portions. After aliqoting the 
serum, the serum was stored at - 8 0 � C until analysis by ELISA. Commercially avail-
able ELISA kits were used to measure serum concentration of osteocalcin (Rat-Mid 
Osteocalcin, Nordic Bioscience Diagnostics A/S, Denmark) and tartrate-resistant 
acid phosphatase 5b (TRAP 5b) (RatTRAP, Immunodiagnostic System Limited, 
United Kingdom). Concentration of osteocalcin and TRAP5b in serum were mea-
sured to analyze bone formation[95] and resorption[141, 71] rate respectively. 
Osteocalcin and TRAP5b ELISA Procedure 
The osteocalcin ELISA (Enzyme-Linked Immunosorbent Assay) kit (Rat-Mid Os-
teocalcin, Nordic Bioscience Diagnostics A/S) and TRAP5b ELISA kit (RatTRAP, 
Immunodiagnostic System Limited) were used to measure the serum concentra-
tion of osteocalcin and TRAP5b enzyme respectively. The osteocalcin ELISA uses 
monoclonal antibody to competitively bind to soluble or immobilized osteocalcin. 
The monoclonal antibody in this kit recognized the mid-molecular part (amino acid 
21 - 29) of the rat osteocalcin protein[115]. The TRAP5b ELISA is a solid phase 
immunofixed enzyme activity assay. 
The kits were stored in a 4 0 C cold room until analysis. All solutions and samples 
were equilibrated to room temperature before use. The assay was performed at room 
temperature. All samples were performed in duplicate. The thawed sample would 
not be stored and used for another measurement. This would prevent the degenera-
tion of osteocalcin and TRAP5b by freeze-and-thaw[14, 141]. The instructions from 
the manufacturers were followed strictly without modification. The absorbance for 
osteocalcin was measured immediately at 450 nm with a reference at 650 nm[127] 
while absorbance for TRAP5b was measured at 405 nm[141]. Calibration curves 
for osteocalcin and TRAP5b were plotted. The concentration of osteocalcin and 
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TRAP5b was calculated from their respective calibration curve. 
TRAP5b ELISA Kit Validations 
The validation of the TRAP5b ELISA kit was performed by Wu et al[Ul]. The 
method validation experiments were conducted for inter- and intra-assay accuracy 
and precision, establishment of sample control, range findings of different population 
groups, selectivity tests, parallelism and stability. The analytical range was 1.00 — 
10.0 U/L and the total errors of lower limit of quantification and upper limit of 
quantification validation samples were 8% and 21%, respectively. Selectivity results 
showed accurate spike recovery among the majority of test samples from target 
populations. Samples were demonstrated to be stable for up to four freeze/thaw 
cycles and for 24 months at -70 士 10�C. 
2.7 Stat is t ical Analysis 
All quantitative data were expressed as mean 士 standard deviation (SD). All analyses 
were performed with SPSS version 16.0 software (SPSS Inc, Chicago, IL, USA) in 
Microsoft Windows XP. One-way Analysis Of Variance (ANOVA) with Bonferroni 
Post Hoc test and two-way ANOVA were performed to analyze difference among 
groups and interaction of Bis and Vib respectively. Statistical significance was set 
at a probability level of 95% (p<0.05). 
Chapter 3 
Results 
In this experiment, bilateral ovariectomy (OVX) and closed femoral fracture were 
performed on 80 SD rats. There was no significant bleeding occurred during the two 
procedures. However, two rats died from the OVX procedure and four were either 
died after the fracture surgery or excluded due to non-transverse fracture. The 
overall rate of success for the creation of transverse fracture was 92.5% (74/80) (Table 
3.1). One rat died unexpectedly during the study for unknown reason. Therefore, 
there was 73 rats left, out of a total of 80 rats, for analysis. The rats with a successful 
surgical procedure showed no surgical complications such as wound infections. All 
rats recovered full weight-bearing walking before commencing treatment (Day 5 
post-fracture). This was comparable to the results in our previous studies which also 
found that the rats regained full weight-bearing before Day 5 post-fracture[76, 129]. 
No panic behaviors and weight loss for all groups were observed during the treatment 
period. Subcutaneous injection of ibandronate, saline, or fluorochromes did not 
cause any complications or death to the rats. 
51 
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Table 3.1: Sample size for four groups (CG, BG, VG, and VBG) at different time points 
(2, 4, 6, and 8 weeks post-treatment). 
Group Week 2 Week 4 Week 6 Week 8 
CG 4 4 4 5 
BG 5 4 5 5 
VG 5 5 5 4 
VBG 5 5 5 4 
3.1 Radiographic Analysis 
3.1.1 Callus Bridging Rate 
From the weekly lateral and AP radiographs, radio-opaque external callus was ob-
served around the fracture site from week 1 to week 8 in all groups. A callus gap 
at the fracture line was located between the calluses from the proximal and distal 
bone fragments. The size of the callus gap decreased over the treatment period. VG 
showed the earliest bridging of cortical bone at week 6. Also, CG and VBG bridged 
at week 8 on the serial radiographs respectively (Figure 3,1). BG showed incomplete 
bridging of the callus up to week 8. In addition, VG showed the highest bridging 
rate of cortical bone (100%) and BG had the lowest (20%) (Table 3.2). 
3.1.2 Callus W i d t h and Area 
In quantitative assessment, both CA and CW showed that VG and CG peaked 
at around week 3 and week 4 (Figure 3.2). From week 1 to week 4, the callus 
measurements were increasing for all the groups. However, the trend was different 
for different treatment group from week 4 to week 8. 
Week 1 — 4 
From week 1 to week 4, all callus measurement showed an increasing trend (Figure 
3.2). From week 1 to week 2，VG and VBG showed a comparable increase in CW 
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(from 1.85 to 2.26 mm) and CA (from 13.23 to 17.69 mm 2 ) . At week 3 and week 4, 
the radiological callus measurements for all the groups peaked. The peak values for 
CG were lower than the rest of the groups (CW: 86% of VG, and CA: 86% of VG). 
CG was significantly lower than the other treatment groups in CW (Week 1, 2, 3, 
and 4 with p < 0.01) and CA (Week 2, 3，and 4 with p < 0.05). From week 1 to week 
4, the average CW and CA for BG, VG, and VBG were comparable among each 
other. Therefore, there was no significant difference between these three groups. 
Week 4 - 8 
From week 4 to week 8, BG maintained a plateau trend while VBG showed a drop-
ping trend. At week 8, BG had the largest callus measurements among different 
treatment groups. BG was 30.05% (p < 0.0005) and 50.11% (p = 0.002) greater 
than CG in CW and CA respectively. VBG had the second highest CW and CA in 
the four treatment groups. VG and CG had the smallest callus. At week 8, there 
was no significant difference between CG and VG in terms of CW and CA. VG 
was significantly different from BG in CW (p < 0.0005) and CA (p = 0.003) while 
VG found statistical difference with VBG in CA (p 二 0.005) at week 8. Two-way 
ANOVA showed that there were significant interactions between the LMHFV and 
ibandronate for CA at week 6 (p = 0.045), week 7 (p = 0.005), and week 8 (p = 0.004). 
When analyzing the rate of callus disappearance, from week 4 to week 8, VG 
had the largest drop in CA while CG and VBG had comparable reduction (Table 
3.3). BG showed increasing CA from week 4 to week 8. Similar observations were 
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Table 3.2: Callus bridging rate of the four groups (CG, BG, VG, and VBG) at different 
time points (4, 6, and 8 weeks post-treatment). 
Group Week4 Week 6 Week 8 
CG 30.77% 44.44% 80.00% 
BG 28.57% 30.00% 20.00% 
VG 35.71% 47.22% 100.00% 
VBG 28.57% 44.44% 75.00% 
Table 3.3: Callus area and width percentage changed from week 4 to week 8 for all 
treatment groups. 
Group CA CW 
CG -16.09% -5.04% 
BG 5.39% 2.53% 
VG -24.42% -18.44% 
VBG -12.17% -12.09% 
3.2 ^ C T Analysis 
Microarchitecture analysis using fj,CT was completed. A trend was observed in the 
bone density (BV density) of the callus from week 2 to week 8. When comparing 
Bis-treated groups with non-Bis-treated groups, Bis-treated groups (BG and VBG) 
showed higher BV, BV^, and BV^/TV values but lower BV density from week 2 to 
week 8 (Table. 3.4). 
Week 2 - 4 
Mineralization of callus at the peri-fracture regions was observed on the ju,CT images 
at week 2 (Figure 3.3). At week 2, the 3D image of the fracture callus showed 
mineralized calluses in the peri-fracture regions. The quantitative measurements of 
BV/TV showed that all groups showed an increasing trend in BV/TV from week 2 
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(b) Average callus area measured over 8 weeks radiologically 
Figure 3.2: Changes of callus area and width over 8 weeks period in all groups (CG, 
BG, VG, and VBG) (Error bar represents lSD). a: Callus width, b: Callus area. BG 
maintained a plateau trend while VBG showed a dropping trend. At week 8, BG had the 
largest callus (greater than CG in CW (30.05%, p = 0.002) and CA (50.11%, p < 0.0005) 
respectively), followed by VBG. VG and CG had the smallest callus and there was no 
significant difference among them. Significant interactions for CA at week 6 ^p = 0.045), 
week 7 (p = 0.005), and week 8 (p = 0.004). 
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to week 4. At week 4, CG and VG reached their peaks (Figure 5.1). In addition, 
BV/TV for VG was 19.23% higher than CG (p = 0.003) at week 4, 
Week 4 - 8 
At week 6, BG and VBG reached the peak at week 6. VBG had the largest BV/TV 
. W h e n compared to CG, VBG showed a 43.64% higher than CG (p < 0.0005). In 
addition, a decreasing trend of BV/TV in VBG was observed from week 6 to week 
8 while BG showed a plateau trend (Figure 5.1). This decreasing trend of BV/TV 
observed in VBG was comparable to CG the drop drop in BV/TV in CG at week 6 
to week 8. These two groups showed a 5% decrease of BV/TV from week 6 to week 8. 
At week 8, BV/TV for VG dropped from 19% higher than CG to a comparable level 
to CG at week 8. In addition, from the serial 3D images of the callus, VG showed 
smaller callus gap than the other three groups. CG and VBG showed comparable 
callus gap while BG showed the largest (Figure 3.3). 
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Time CG BG VG VBG 
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Figure 3.3: Serial ^ C T 3D images for different groups (CG, BG, VG, and VBG) from 
week 2 to week 8. 
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Figure 3.4: B V / T V bar graph showed that the normalized bone volume for CG and VG 
peaked at week 4 while BG remained the same level throughout the eight weeks period. 
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3.3 H i s t o m o r p h o m e t r i c Analysis 
3.3.1 B o n e Mineral ization R a t e 
Week 2 
As mentioned in section 2.6.3，MAR for 2 weeks treatment groups was not included 
because callus mineralization occurs during mid-second week post fracture (10 — 14 
days post fracture)[33]. Calcein green (the green fluorochrome band) labelled the old 
femoral cortical bone while xylenol orange (the orange fluorochrome band) labelled 
the newly mineralized callus (Figure 3,5). 
mwm 
^^^^^^Kufmkw^^^^^^^^^^^^^^^^^^^^ 
^ K ^ ^ H 
^ ^ ^ ^ ^ ^ H 
• n H 
Figure 3.5: Undecalcified histology image of a callus at week 2. The fluorochrome bands 
labelled the old cortical bone (green band) and the newly mineralized callus (orange band). Week 4 - 8 
The two fluorochromes labeled the fracture callus on all samples from week 4 to 
week 8. Fluorochrome labeled entire region of interest in all groups from week 4 
to week 8. Distinct bands of fluorochrome were also found in all groups (Figure 
3.7). Both qualitative (Figure 3.7) and quantitative analysis (Figure 3.6) showed 
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that VG had the highest MAR (9.07 士 0.75 ^m|day, p < 0.01 compared to all other 
groups) at week 6. CG and VBG showed lower MAR than VG (CG: 65.05% of VG 
(p = 0.009), VBG: 56.89% of VG (p = 0.0004)). Moreover, there was no significant 
difference between CG and VBG. BG had the lowest MAR at week 4 and week 6. 
At week 6, BG was 45% of VG (p < 0.0005). Two-way ANOVA showed that there 
was interaction that was marginal significance between LMHFV and Bis at week 6 
(p = 0.072). At week 8, the MAR dropped and there was no significant difference 
among groups. 
1 5 1 • CG 
• BG 
? D V G 
I 1 0 ' . I D V B G 
H _ _ n 
4 6 8 
Week 
Figure 3.6: Average mineral apposition rate (MAR) of all treatment groups from week 4 to 
week 8 post-treatment. VG showed the highest MAR at week 6. There was no significant 
difference between groups at week 8. (Error Bar represents lSD) 
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Figure 3.7: Undecalcified histology for different groups (CG, BG, VG, and VBG) from 
week 4 to week 8. All groups at all time points showed distinct bands of fluorochromes. 
There was no observable difference between groups at week 4 and week 8. At week 6, 
VG showed the longest distance between the two fluorochrome bands while VBG was the 
second longest. 
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3.4 Bone Marke r s Analysis 
3.4.1 Osteocalcin 
A calibration curve was obtained and th_e line of best fit had a R2 value of 0.99041. 
Serum concentration of osteocalcin showed a decreasing trend for VG from week 
2 (128.31 士 40.80 ng/mL) to week 8 (42.95 士 25.99 ng/mL). In addition, CG and 
VBG showed peaks at week 4 and week 6 respectively (Figure 3.8). VG showed 
significantly higher osteocalcin concentration than CG in week 2 (4.79 times of 
CG, p < 0.0005), week 6 (2.56 times of CG, p 二 0.046) while showed no significant 
difference at week 4 (p = 0.599)and week 8 (p = 0.444). Osteocalcin concentration 
for BG peaked at week 4 (52.93 士 14.16 ng/mL) and dropped to minimal level at 
week 6 to week 8. 
3.4.2 T R A P 5 b 
A calibration curve was obtained and the line of best fit had a R2 value of 0.9908. 
Serum concentration of TRAP5b for VG peaked at week 2 and week 8 while a 
decreasing trend was observed for CG (Figure 3.9). From week 2 to week 8, CG had 
significantly higher serum concentration of TRAP5b than BG {p < 0.0005 from week 
2 to week 8). At week 2, TRAP5b serum concentration for VG was significantly 
lower than CG (p = 0.001). In addition, there was no significant difference between 
VG and BG (p - 0.140) while VBG had the lowest !evel. CG showed the highest 
TRAP5b concentration in week 2 (3.60±0.84 U/L, p < 0.0005 for comparison to other 
groups). At week 8, VG shown significantly higher TRAP5b serum concentration 
than CG (p = 0.006). Two-way ANOVA showed that there was interaction that was 
marginal significance between LMHFV and Bis at week 8 (p « 0.066). The serum 
concentrations of TRAP5b for BG and VBG were almost not detectable from week 
4 to week 8. 
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Figure 3.8: Serum concentration of osteocalcin over 8 weeks treatment. Serum concentra-
tion of osteocalcin for VG was the highest at week 2 while concentration for CG peaked 
at week 4. After the peaks, both group showed a decreasing trend. At week 8，the serum 
concentration for VG was significantly higher than CG (p 二 0.444). (Error Bar represents 
lSD) 
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Figure 3.9: Serum concentration of TRAP5b over 8 weeks treatment. At week 2, TRAP5b 
serum concentration for VG was significantly lower than CG (p 二 0.001). There was no 
significant difference between VG and BG (p = 0.140). The serum concentrations of 
TRAP5b for BG and VBG were almost not detectable from week 4 to week 8. At week 
8, VG showed significant difference in TRAP5b serum concentration (p < 0.0005). (Error 
Bar represents lSD) 
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3.4.3 Summary 
To summarize, LMHFV treated group had the fastest decrease in callus measure-
ments with respect to radiological and microarchitectural assessments. VG had the 
fastest drop in CA and CW, and BV/TV; whereas, a plateaued trend in BG and 
VBG was observed. With respect to callus mineralization, VG had the highest MAR 
at week 6. Biochemical analyses of bone markers found that the serum concentra-
tion of osteocalcin and TRAP5b were higher compared to other groups at week 8. 
A summary of all the statistical significant results is presented in table 3.5. 
CHAPTER 3. RESULTS 68 
Table 3.5: Summary of all the statistical significant results (p < 0.05) from radiological, 
microarchitectural, histomorphometric, and biochemical analyses. 
Assessment Week 2 Week 4 Week 6 Week 8 
Callus Width V G > C G V G > C G B G > V G B G > V G 
and Area B G > C G B G > C G B G > C G B G > C G 
V B G > C G V B G > C G VBG>VG ^VBG>VG 
V B G > C G * L x B 
*LxB 
BV/TV BG>VG VG>CG BG>VG BG>VG 
BG>CG BG>VG BG>CG BG>CG 
VBG>CG BG>CG VBG>VG VBG>VG 
VBG>VG VBG>BG VBG>CG 
VBG>CG VBG>CG 
Mineral N / A V G > B G 
Apposition VG>VBG 
Ra^te VG>CG 
Semm VG>BG CG>BG VG>BG 
Osteocalcin VG>VBG CG>VBG VG>CG 
V G > C G VBG>BG 
L x B VBG>CG 
Serum VG>VBG VG>BG VG>BG VG>BG 
TRAP5b CG>VG CG>BG VG>VBG VG>VBG 
CG>BG CG>VBG CG>BG VG>CG 
CG>VBG L x B CG>VBG CG>BG 
L x B CG>VBG 
Note: N / A represents that no such measurement was taken; L x B represents that 2-way 




This is a factorial design study in vivo, looking into the effect of a treatment in 
the presence or absence of a known antagonist. It was performed to study the ef-
fect of LMHFV on bone remodeling. The presence of a known antagonist which 
has the same or opposite effect of the unknown treatment would change the effect 
of the treatment. The effect of LMHFV on bone remodeling in fracture healing 
was investigated directly by comparing difference in fracture healing between VG 
and CG, and indirectly by comparing how bone remodeling under LMHFV stim-
ulation changes in the presence of Bis. LMHFV enhanced early phase of fracture 
healing through enhanced callus formation and faster mineralization which echoed 
our previous studies[129, 76]. The findings suggested that LMHFV hastened the 
disappearance of callus and partially reversed the delay of bone remodeling by iban-
dronate. These findings implied that LMHFV enhanced bone remodeling. 
4.1 L M H F V Enhanced Bone Remodel ing 
As mentioned previously (Section 1.2), the traditional model of fracture healing is 
divided in four stages: inflammation, soft callus (fibrocartilage) formation, hard 
callus formation, and bone remodeling[126]. However, there is significant overlap 
between different stages and callus is not a homogeneous structure. Therefore, it 
would be difficult to determine the stage of fracture healing for a callus. Since all 
69 
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radiological and micro-architecture measurements of callus for CG and VG peaked 
at week 3 to week 4 (Figure 3.2), bone remodeling for osteoporotic bone fracture 
should start around this period because bone remodeling occurs after callus reaches 
its maximal size when catabolism dominates over anabolism[81]. This finding echoed 
with our previous study in osteoporotic rats which bone remodeling was observed 
around week 3 to week 4[129]. In addition, in our previous study using young 
SD rats, bone remodeling started around week 2[76]. Since fracture healing of 
osteoporotic bone would be delayed, bone remodeling for normal rat began at week 2 
would further confirmed that bone remodeling for OVX rat would commence around 
week 3 to week 4[89]. Therefore, fractures in OVX rats would start bone remodeling 
around week 4. 
LMHFV enhanced bone remodeling in fracture healing. VG showed a faster 
drop than CG in CW (Figure 3.2a) and CA (Figure 3.2b) in radiographic analysis, 
and BV/TV in micro-architecture analysis (Figure 5.1) from week 4 to week 8. As 
mentioned previously (Section 1.3.2), our study in normal[76] and aged SD rat[129] 
also observed enhanced rate of disappearance of callus. VG also demonstrated an 
increased serum concentration of osteocalcin (Figure 3.8，on week 6 and week 8) and 
TRAP5b (Figure 3.9, on week 8), and a higher MAR than CG (Figure 3.6). These 
results suggested enhanced bone remodeling as a result of LMHFV treatment. 
4.1.1 L M H F V Reversed Bis Inhibition on Bone Remodel ing 
Ibandronate is one of the nitrogen-containing bisphosphonates available on the mar-
ket. Ibandronate was more potent than etidronate, clodronate, pamidronate, and 
alendronate[29] (Refer to section 4.4.2 for details). In this study, ibandronate was 
the bisphosphonate that was used to inhibit bone remodeling. LMHFV partially re-
versed the inhibitory effect by Bis in bone remodeling. This suggested that LMHFV 
had an opposite effect on bone remodeling than Bis. After callus in BG reached 
its maximal size in week 4，a plateau trend in radiographic analysis of CW (Figure 
3.2a) and CA (Figure 3.2b), and BV/TV in ^CT (Figure 5.1) was observed. This 
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suggested that weekly injection of Bis can cause delay in bone remodeling due to 
its anti-catabolic effect and this was observed in other fracture healing studies with 
an anti-catabolic intervention[81, 90, 104]. However, with the presence of LMHFV, 
VBG showed higher bridging rate, faster decrease in CA and CW at week 6 to week 
8, and higher MAR at week 6 (Figure 3.6 and 3.7) than BG. In addition, two-way 
ANOVA analysis in CA and CW showed significant interaction between LMHFV 
and Bis, which also suggested that inhibition of bone remodeling by Bis was di-
minished by the presences of LMHFV. Therefore, LMHFV might have an opposite 
effect to Bis which might enhance bone remodeling. 
4.1.2 L M H F V Effect on Osteoclastic Resorption During Bone Remod-
eling 
Bone remodeling is the final stage of the classical fracture healing model which re-
places woven bone in hard callus with laminar bone (Section 1.2). The remodeling 
process is coupled between bone resorption followed by bone formation[126, 130]. 
Osteoclast is the key cell type which is responsible for the resorption of mineralized 
bone[126, 130]. LMHFV might have stimulated osteoclastic resorption in bone re-
modeling which led to the increase in bone remodeling. The highest MAR at week 
6 (Figure 3.6) and increased osteocalcin serum concentration in VG (Figure 3.8) 
suggested that LMHFV enhanced mineralization and osteoblastic activity respec-
tively. Since the activity of osteoblast and osteoclast are coupled[130], this suggested 
that osteoclast activity might also be enhanced by LMHFV. Enhanced osteoclas-
tic resorption by LMHFV was further supported by the increased TRAP5b serum 
concentration at week 8 (Figure 3.9). Higher serum concentration of TRAP5b was 
found in VBG than BG during bone remodeling. Since TRAP5b is a bone marker 
for resorption and found specifically in osteoclast[130, 141] increased concentration 
of TRAP5b also suggested higher resorption in VBG. Therefore, osteoclasts activity 
might also be enhanced by LMHFV. 
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4.2 E n h a n c e d F rac tu re Heal ing by L M H F V 
LMHFV enhanced early phase of fracture healing in osteoporotic bone. VG showed 
higher callus measurement from radiographs (Figure 3.2) and ^ C T (Table 3.4), and 
higher bridging rate than CG (Table 3.2) which implied that LMHFV improved 
fracture healing. VG also showed higher bone density than CG and increased min-
eralization rate which suggested that LMHFV enhanced mineralization of fracture 
callus. Similar results were found in our previous stndy[129]. In the current study 
and our previous study using aged OVX rats, LMHFV showed 10-20% increase 
in fracture healing, which were observed between VG and CG, while 25—30% was 
observed in young normal rats[76, 129]. In addition to the radiological and microar-
chitectural enhancement, VG showed higher osteocalcin concentration in serum than 
CG from week 2 to week 4 (Figure 3.8). This biochemical analysis of bone forma-
tion marker was a new finding in addition to our previous results. The results from 
the biochemical analysis were comparable to results from our previous experiments. 
This further supported that LMHFV enhanced callus formation. 
4.2.1 Acceleration of Fracture Healing by L M H F V 
Our previous study on aged OVX rat showed morphology of the callus at week 2, 
4, and 8 while study in young rat showed data on week 1，2, and 4[76, 129]. There 
was a lower ratio of cartilage area to callus area (Cg.Ar/Cl.Ar) in groups treated 
with LMHFV than control groups at week 4 and week 8 for young and aged rats 
respectively. The lowering of the Cg.Ar/Cl.Ar suggested that more woven bone was 
formed in the callus. Woven bone is mineralized tissue and stiffness (hardness) of the 
fracture callus closely correlates with its calcium content[33]. This also implied that 
in the later stage of fracture healing, callus with lower Cg.Ar/Cl.Ar would be more 
stable. However, no significant difference was detected in this ratio for these two 
studies[76, 129]. Therefore, weekly histological assessment on the callus morphology 
might be required in order to detect the acceleration of fracture healing progression 
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significantly. However, the accelerated trend was still observed. 
The earlier peak of osteocalcin in VG than CG suggested faster progression of 
fracture healing by the effect of LMHFV. Osteocalcin is a noncollagenous protein 
found in bone (Please refer to Section 1.1.1 and 4.4.3 for details). Osteocalcin expres-
sion was initiated in Day 9 to Day 11 post-fracture and peak expression was observed 
around post-fracture Day 15 in non-osteoporotic rats[31, 68]. The peak expression 
of osteocalcin in the current study was found at week 4 post-treatment which was 
post-fracture Day 26 in CG. Therefore, by taking into account the delay of fracture 
healing caused by osteoporotic bone, this matched the peak expression found in 
other fracture healing studies. In addition, the peak expression of osteocalcin for 
VG was observed at week 2 post-treatment, which is equivalent to post-fracture Day 
19. As mentioned previously (Section 1.2)，fracture healing was classified into four 
overlapping stages: Hematoma formation, soft callus formation, hard callus forma-
tion, and bone remodeling. Since bone remodeling was the last stage of fracture 
healing and it occurred around week 4, therefore hard callus formation must have 
initiated before week 4. Osteocalcin gene expression was detected in the hard callus 
during endochondral ossification and remodeling[68]. However, during intramem-
branous bone formation or at any time in the soft callus, osteocalcin expression was 
not found[68]. Since the peak of osteocalcin concentration for VG was at week 2 
while the peak for CG was at week 4, this might suggest that endochondral ossifica-
tion, the process that modifies soft callus into hard callus, in VG might have started 
earlier than CG. This imply that not only LMHFV enhanced fracture healing, it also 
accelerated fracture healing progression so the callus underwent remodeling earlier 
than those that were not treated with LMHFV. 
4.2.2 L M H F V Inhibits Osteoclast Act iv i ty in the Early Phase of Healing 
LMHFV appeared to suppress osteoclast activity in early fracture healing when the 
bone was undergoing endochondral ossification. Serum concentration of TRAP5b 
was suppressed to the level comparable to BG under LMHFV treatment and lower 
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than the concentration in CG (Figure 3.9). Daily LMHFV inhibited bone resorp-
tion in growing skeleton which is also undergoing endochondral ossification[81, 142]. 
LMHFV might have a similar effect on fracture bone which is undergoing a similar 
process[81]. Therefore, as the fracture repair process convert from endochrondral 
ossification to intramembranous ossification, the suppression of LMHFV on the bone 
resorption decreased as it was observed in the increased expression of TRAP5b in 
VG to a level comparable to CG in week 4 to week 8. Inhibition of osteoclast activ-
ity in early phase of fracture healing was reported by other mechanical stimulation 
studies in vitro. LMHFV stimulation (0.3 g with 30, 60, or 90 Hz) on osteocytes-
like cells decreased RANKL，an osteoclast differentiation protein[73]. The condi-
tioned medium collected from vibrated osteocytes inhibited the formation of large 
osteoclast. Another biophysical stimulation study using low-intensity ultrasound 
stimulation (LIPUS) in vitro on alveolar mononuclear cell and osteoblast cells co-
culture found an increase in osteoblast count and a decrease in osteoclast count[132]. 
These findings substantiate to our study that mechanical stimulation might decrease 
osteoclast differentiation and survival in the early stage of fracture healing. 
4.2.3 L M H F V Stimulates Osteoblast Act iv i ty in the Early Phase of 
Healing 
From previous sections (Section 4.2.1 and 4.2.2), LMHFV inhibited the activity of 
osteoclast during the early phase of fracture healing while the progression of frac-
ture healing was accelerated. This suggested that the effect by LMHFV during 
the early phase of fracture healing might depended on osteoblast. As mentioned, 
biomechanical stimulation by LIPUS on alveolar mononuclear cell and osteoblast 
cells coculture found an increase in osteoblast count and a decrease in osteoclast 
count[132]. Therefore, LMHFV might enhance the proliferation and differentiation 
of osteoblast. The increased osteocalcin concentration might imply that bone for-
mation by osteoblast was enhanced because osteocalcin is a protein produced by 
osteoblast for bone formation[95]. Therefore, the enhanced of fracture healing by 
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LMHFV might be due to LMHFV stimulation on osteoblast. 
4.3 Bis Delays F rac tu re Heal ing 
Bis seems have no effect on the early phase of fracture healing. Ibandronate was 
injected weekly throughout the eight weeks treatment period. Initially, there was no 
significant difference between BG and other groups in CW, CA, or B V / T V analysis 
(Figure 3.2a, 3.2b, and 5.1 respectively). This suggested that Bis did not affect the 
early endochondral fracture repair[90]. However, Bis dosage was effective in sup-
pressing resorption. As mentioned previously, BG showed delayed bone remodeling 
with respect to radiological, micro-architectural, and biochemical analysis. This 
phenomenon was expected and observed in other fracture healing studies that used 
bisphosphonate[90, 18, 87]. Cao et al. administrated alendronate (10fj,g/kg/day) for 
6 weeks and 16 weeks in OVX femoral fractured SD rat and found that rats adminis-
trated alendronate had largest callus. Furthermore, at week 16, the original cortical 
shell remained but became porous in alendronate group while a new cortical shell 
and marrow cavity were forming in OVX control group. Also, Cao et al found that 
callus of alendronate group was made up of woven bone and the original fracture 
line was still observable[18]. This phenomenon was also found in this study since 
the bridging rate for BG group at week 8 was only 20% while it was 80% for CG 
(Table 3.2). Therefore, this result suggested that the large callus in bisphosphonate 
group appeared to be an adaption to provide better stability at fracture. 
Inhibition of bone remodeling might be due to inhibition of angiogenesis dur-
ing fracture healing. Other than bone resorption, osteoclasts may also involved in 
the stimulation of angiogenesis[17]. In addition to inhibition on osteoclasts, bispho-
sphonate might also inhibit endothelial progenitor cells, which are important for 
angiogenesis[144]. Since angiogenesis plays an important role during intramembra-
nous bone formation and endochondral ossification[56], inhibition of angiogenesis 
would also delay bone remodeling. This delay in bone remodeling might have a neg-
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ative effect on fracture strength since bone strength is determined by bone volume, 
micro-architecture of bone, and bone mineralization[135]. Even though bisphospho-
nate increases the callus volume and increased or unchanged of mechanical strength 
of the callus[78], delay in bone remodeling caused a disorganized matrix structure 
in the callus which would decrease the quality of tissue[90, 18]. Therefore, bispho-
sphonate might have a negative effect on fracture healing even though there is no 
significant difference in mechanical strength at the fracture site. 
Different effects between LMHFV and Bis on callus size and morphology 
Fracture healing results in a gradual decrease in micromotion between fractured 
bones[33, 140]. In the early phase of fracture healing, the fracture causes instabil-
ity of the bone and micromotions[32]. The micromotion between the fragments 
is believed to govern the type of tissue formed between fracture fragments[33]. 
Hypertrophic non-union of the fracture would occur if the mechanical stability is 
insufficient[24]. 
Hematoma, soft callus, hard callus are stabilizing structure that is made of dif-
ferent tissues to stabilize the fracture site. LMHFV provides more micromotions 
and mechanical loading at the fracture site than sham. This would induce the for-
mation of larger soft callus at the beginning of the healing (Before week 2)[24, 53]. 
On the other hand, BG and CG should receive the same amount of loading and 
micromotions so they should have the same size callus (Before Week 2). For the 
formation of hard callus, LMHFV accelerates the endochondral bone repair which 
enhances the formation of hard callus[53]. 
The mechanical strength of callus depends on the callus material and the ge-
ometry of the callus[135]. After week 2, hard callus, which was made of woven 
bone, was formed and bone remodeling started. As mentioned in section 1.2, in 
bone remodeling, woven bone would be replaced with lamellar bone. During bone 
remodeling, this study have shown that LMHFV stimulates the activities of os-
teoblasts and osteoclasts which would enhance bone remodeling (Refer to section 
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4.1 for details). In addition, LMHFV might increase the micromotions and mechan-
ical loading at the fracture site which would induce osteogenesis through the process 
of mechanotransduction[136]. Therefore, bone remodeling in VG was enhanced and 
replaced mechanically inferior woven bone with mechanically superior lamellar bone. 
As a result, callus in VG would be made of both woven bone and lamellar bone. 
Bis inhibited osteoclast activity and caused inhibition of remodeling throughout 
fracture healing. Bone can be directed osteogenesis to where it is most needed to 
improve bone strength[135]. One way that bone adapts to mechanical stress and 
enhance stability with a mechanically inferior material is by increasing the periosteal 
radius of bone. As explained by Turner[135], the second moment of area (/) , impor-
tant for the callus to resist bending[33], can be calculated from the periosteal radius 
( r p ) and the endosteal radius ( r e ) 
I = l ^ - r i ) 
The rp is about 1.8 tims re in mammalian long bones[135]. Therefore, the equation 
can be modified to 
I = 0.71r^ (4.1) 
Equation 4.1 shows that periosteal radius is an important factor for bone structure 
rigidity[135]. Therefore, increase the periosteal radius by increasing the callus size 
would improve the stability of fracture in BG . Consequently, with bone remodeling 
inhibited, callus in BG would be made of woven bone and larger compared to CG. 
For VBG, the remodeling should be delayed by Bis (LMHFV enhances remod-
eling while Bis inhibits remodeling). Callus of VBG would have a large amount 
of mechanical loading and micromotions which would increase the callus size. In 
addition, the callus of VBG would be made of woven bone at the beginning of bone 
remodeling due to inhibition of remodeling by Bis. However, as the inhibition on re-
modeling is reversed, the callus size should drop as the callus remodels into lamellar 
bone. 
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At week 8, the callus of VG should be mainly made up of lamellar bone while 
CG should be made up of woven bone and lamellar bone. VG has a higher ratio of 
lamellar bone to woven bone as compared to CG because there is higher mechanical 
loading m VG and callus size of VG is comparable to CG (Section 4.1). Since 
Bis inhibited remodeling, callus in BG should be mainly made up of woven bone. 
Lamellar bone should be found in the callus of VBG because LMHFV partially 
reversed the inhibition of remodeling by Bis (Section 4.1.1). 
4.4 Expe r imen ta l Design 
4.4.1 Inhibit ion Study 
In order to investigate in the effect of LMHFV on bone remodeling, an factorial 
design study, a classic research methodology for investigation on the effect of a new 
drug[137], would be sufficient. The magnitude of effect of the unknown drug would 
change if it has same or opposite effect of the known an tagon i s t�By studying how 
the effect of unknown drug changes in the presence of a known antagonist, the effect 
of the unknown drug can be verified. Therefore, interference to a key component in 
bone remodeling should have an effect on bone remodeling. 
Osteoblast is responsible for bone formation while osteoclast is responsible for 
resorption and removal of old bone. During fracture healing, bone resorption is 
coupled with bone formation to resorption[88, 85，125]. Osteoclast removes dead 
bone during early phase of fracture healing and replaces the less mechanical support 
woven bone with high mechanical strength laminar bone in bone remodeling[125]. 
Therefore, to study the effect in bone remodeling by LMHFV, a known antagonist 
would be used to inhibit osteoclast activity. 
Bisphosphonate can be used in an inhibition study and act as a known antagonist 
that inhibits bone remodeling. As mentioned previously, an inhibition study is a 
traditional approach to study the effect of an unknown treatment. Bisphosphonate 
inhibits osteoclast activity and causes inhibition of bone remodeling. Bisphospho-
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nate binds to the calcium hydroxyapatite crystal selectively[103, 121]. Bisphospho-
nate is released and taken up by osteoclast during resorption and causes osteoclast 
apoptosis[103, 121]. This would lead to decoupling of the osteoblast-osteoclast activ-
ity and inhibit bone remodeling[103,121, 130]. Therefore, administration of LMHFV 
in the presence or absence of bisphosphonate allowed investigation on the effect of 
LMHFV on bone remodeling in fracture healing. 
4.4.2 Bisphosphonate Injection Protocol 
Choice of Bisphosphonate 
As mentioned previously (Section 4.41), bisphosphonate was used as a tool to in-
hibition bone remodeling in order to study the effect of LMHFV on bone remod-
eling. Alendronate, ibandronate, and risedronate[91] are the bisphosphonate that 
are commonly available on the market. Ibandronate was chosen for bisphosphonate 
treatment. The pharmacokinetics of ibandronate are studied preclinically[93, 5]. 
The efficacy of ibandronate was higher than other available bisphosphonates (Fig-
ure 4.1). In addition to a lower E D 5 0 , the effective dose that creates 50% response, 
than alendronate in vivo, EC 5 0 , the effective concentration that produces a 50% 
of response, for ibandronate (3.5 x 10" 1 0 mol/L) is lower than alendronate (2 x 10" 9 
mol/L) in vitro[S0]. In addition, ibandronate has the second highest relatively higher 
affinity and potency (Table 4.1). Therefore, ibandronate is a better bisphosphonate 
of choice since less amount of drug is required to achieve the same level of bone 
resorption inhibition. 
Route of Administration 
The bioavailability are low for most of the bisphosphonate that are administrated 
orally because they are poorly absorbed from the gastrointestinal tract (GI tract)[5]. 
The oral bioavailability of ibandronate was estimated to be less than l%[5, 39]. In 
addition, oral absorption of bisphosphonate in rats is higher in the fasted state 
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Figure 4.1: Dose-response curve of different bisphosphonates (Ibandronate, Pamidronate, 
Aldendronate, Clodronate) for inhibition of bone resorption in rats[35, 92]. Ibandronate 
has the highest efficacy (ED50 « 0.001 mg phosphorus/kg/day). (Reprinted from Epstein 
et al. 2005)[35] 
Table 4.1: Affinity and potency of different commonly available bisphosphonates 
(Etidronate, Alednronate, Risedronate, Ibandronate, and Zoledronate). Zoledronate and 
Ibandronate have the highest and second highest potency and affinity out of the five 
bisphosphonates compared. (Source: Russell et al. 2006)[120]. 
Bisphosphonate R 1 R 2 Potency Affinity* 
E t i d r o n a t e O H C H 3 1 1 .19 
Alendronate OH C H 2 C H 2 C H 2 N H 2 100 - 1000 2.94 
Risedronate OH CH 2-3-pyridine 1000 -10000 2.19 
Ibandronate OH C H 2 C H 2 N ( C H 3 ) ( C 5 H n ) 1000 - 10000 2.36 
Zoledronate OH CH 2 -imidazole >10000 3.47 
Note: *Jn vitro HAP avidity [KL/106 Lmol" 1] 
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than in the fed state[80]. The plasma concentration of ibandronate is reduced when 
ibandronate is administrated after meal[5]. 
There is no significant difference in efficacy when bisphosphonate is given by in-
traperitoneal, intramuscular, or subsutaneous administration. However, the sodium 
salt or calcium salt from bisphosphonate might cause pain and tissue necrosis at 
the site of injection after long term injection[80]. Therefore, lowering the dosage of 
bisphosphonate used might decrease the chance of tissue necrosis and pain. Since 
the efficacy of ibandronate is the highest of the available bisphosphonate (Section 
4.4.2), the tissue damage and pain might be minimized. 
Frequency of Injection 
The effects of bisphosphonate depends on the total dose administrated than the 
dosing frequency[8, 120]. The dosing regimens of ibandronate were studied in OVX 
rats. Daily ibandronate and three intermittent dosing regimens (injection every two 
week, four weeks, or six weeks) with the total administrated dose showed equivalent 
effect on bone mass after one year of treatment (Figure 4.2)[8, 120]. Therefore, the 
dosing regimen would not affect the efficacy of ibandronate as long as the same 
dosage {l^g/kg/day) is administrated. 
4.4.3 Individual Analysis of Bone Formation and Resorption 
As mentioned previously (Section 1.2), fracture healing is a coupled process of bone 
formation and bone resorption. In order to confirm the effect of LMHFV on bone 
formation and investigate the effect of LMHFV on bone resorption, measurements 
which allows assessment on the anabolic and catabolic activity separately are re-
quired. However, radiological assessments do not allow measurements on bone for-
mation or bone resorption separately. 
Bone markers concentration analysis provides a noninvasive tool to assess change 
in bone metabolism. They are useful when monitor bone formation and bone re-
sorption specifically. They can be used to detect both short- and long-term changes 
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Figure 4.2: Effect of daily and different intermittent dosage regimens on bone resorption 
in aged OVX rats[120]. The same total amount of ibandronate was given in daily injec-
tion and intermittent injections.There was no significant difference between the different 
injection regimen. (Reprinted from Russell et al. 2006)[120] 
in bone turnover[95]. An ideal marker should be tissue specific，only reflect only one 
process, and easily measured by specific and sensitive techniques[71]. 
Bone Formation Marker 一 Osteocalcin 
Bone formation markers are proteins that are secreted by osteoblasts. Osteocal-
cin is an established marker of bone formation[95]. It is a noncollagenous protein 
found in bone[95]. The function of osteocalcin is unknown but it has a high affin-
ity to bone minerals because the negatively charged osteocalcin is attracted to the 
positively charged ions in bone mineral. Serum osteocalcin has been shown to cor-
relate with bone formation rate and calcium accretion and no correlation with bone 
resorption[95]. Osteocalcin concentration showed rapid response to glucocorticoid 
therapy and estrogen. In addition, osteocalcin in serum increased after fracture 
for at least 3 months post-fracture[95]. Therefore, osteocalcin serum concentration 
would correctly reflect changes in bone formation during fracture healing. 
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Figure 4.3: The anabolic and catabolic response during normal fracture healing. Figure 
4.3a shows tha t fracture healing is a coupled process of bone formation (anabolic) and bone 
resorption (catabolic). Figure 4.3b shows the trend observed on x-rays and " C T are the 
net result of bone formation and resorption. When anabolism dominates over catabolism, 
bone accumulates. On the other hand, resorption of callus in bone remodeling occurs 
when catabolism dominates over anabolism[81]. (Reprinted from Little et al. 2007) [81] 
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Bone Resorption Marker — TRAP5b 
Bone resorption may be assessed by measuring collagen degradation products, non-
collagenous proteins of the bone matrix, or the enzymes expressed and secreted 
by osteoclast during bone resorption[71]. TRAP consists of two isoforms, 5a and 
5b[71, 141] . TRAP5a are found in macrophages and dendritic cells while TRAP5b is 
the predominant form found in osteoclast[71, 141]. Serum concentration of TRAP5b 
was measured by ELISA in order to measure osteoclast activity accurately. Serum 
samples of TRAP5b were stable for up to four freeze/thaw cycles and 24 months 
at -70 士 10�C[141]. The bone resorptive effect in human was reflected by the serum 
concentration of TRAP5b[141]. Furthermore, the antibody that was used in ELISA 
would specifically bind to the active TRAP5b but not the inactive fragments[55, 
141]. TRAP5b concentration correlates well with histological analysis of bone 
resorption[21]. TRAP5b concentration in serum was measured in patients with 
renal osteodystrophy disease. These patients often presented with secondary hy-
perparathyroidism (increased serum PTH concentration) and increase osteoclast 
activity[21]. Serum TRAP5b level correlated with serum interact PTH concentra-
tion and bone histological assessment of bone resorption such as number of osteoclast 
per bone area and osteoclast area per bone surface[21]. TRAP5b showed response 
to antiresorptive therapy with a lower biological variability. Since TRAP5b is stable 
and correlates with histological bone resorption assessments, measuring TRAP5b 
serum concentration would correctly reflect the bone resorption activity. 
4.5 Clinical Implicat ions 
4.5.1 L M H F V Enhanced Remodel ing 
LMHFV showed anabolic effect on fracture healing in this study and previous 
studies[53, 76, 129, 69]. As mentioned previously, LMHFV showed anabolic ef-
fects on fracture healing by accelerated callus formation and mineralization, and 
enhanced mechanical strength at the fractured site in both normal adult and aged 
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osteoporotic rats[129, 69]. LMHFV also enhanced the endochondral ossification in 
bone repair[53]. Moreover, the current study showed that LMHFV enhance bone 
remodeling. This suggested that LMHFV might be beneficial to patient and admin-
istrated throughout the process of fracture healing. The healing stage of the fracture 
would not affect the effect of LMHFV. Therefore, the enhancement of LMHFV is 
prolonged and may benefit patients in different stage of healing. 
4.5.2 Bisphosphonate Delayed Remodel ing 
The administration of Bis might have a negative effect on the healing of fracture. 
As mentioned in Section 4.3, Bis delays bone remodeling in fracture healing. In 
addition, the microarchitecture of the bone is weakened. The cortical shell of the 
bone became porous and the original fracture line was still observable. Even though 
large callus measurements were the result of bisphosphonate treatment, but this 
increase in callus appeared to be only an adaption to provide better stability at 
the fracture. Therefore, this suggested that Bis delays fracture healing and this 
might be a negative effect. This suggested that it might be necessary to discontinue 
administration of Bis to patients who have fracture and were taking Bis. 
4.6 Limita t ions 
4.6.1 Measurement of Bone Resorption 
Bone remodeling during fracture healing is a coupled process of both bone formation 
and bone resorption. The limitation of this study was that there was no direct mea-
surement ofbone resorption. A commonly use method to measure resorption directly 
is by counting the number of osteoclasts. However, the addition of bisphosphonate 
in this study would cause osteoclast apoptosis. It would be difficult to differentiate 
osteoclasts that are undergoing apoptosis and functional osteoclasts[67, 52，139]. 
Bone biopsy of the patients who took three years of oral alendronate were examined 
and showed an increase in the number of normal osteoclast by 2.6 times[139]. In 
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addition, 27% of these osteoclasts were hypernucleated with 20 to 40 nuclei and 
20% to 37% of these were apoptotic[139]. In addition, the morphology of normal 
osteoclasts are similar to these apoptotic hypernucleated osteoclast. Normal osteo-
clasts are also large and multinucleated with up to 50 nuclei[49]. Therefore, this 
method may over-estimate the number of osteoclast and under-estimate the effect 
of bisphosphonate. As mentioned previously (Section 4.4.3), serum concentration 
of TRAP5b was measured by ELISA in order to measure osteoclast activity accu-
rately. This is because serum TRAP5b level correlated with serum concentration of 
interact PTH and bone histological assessment of bone resorption. 
4.6.2 Osteoporotic Fracture Mode l 
Osteoporotic fracture model was used in order to study the effect of LMHFV on 
bone remodeling in fracture healing. As mentioned previously (Section 1.4.3), os-
teoporosis delays fracture healing even though healing goes through all the normal 
stages. One of the advantages of using this fracture model is that the prolonged 
fracture healing allowed detailed observation of each healing stage. If normal adult 
rats were used, the healing process would be shorten to just four to five weeks[101]. 
This might not allow accurate investigation on bone remodeling with the current 
methods such as the mineral apposition rate. Therefore, it would be difficult to 
observe difference in MAR between different groups. The second advantage of us-
ing OVX-induced osteoporosis model is that it is an appropriate representation of 
elder human subjects. According to the FDA guidelines for the animal models for 
osteoporosis, OVX rat model mimics postmenopausal cancellous bone loss and it is 
a suitable model for evaluation of potential therapeutic agents for the prevention 
of osteoporosis[134]. Therefore, the results obtained from the current study in rat 
would be the best representations of the effect on humans. 
Closed femoral fracture model in rats were used to study the effect of LMHFV 
on bone remodeling. Rat is a commonly used model to study fracture healing[101]. 
The rat model is typically more predictable and practical when performing both 
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surgery and analyses than mouse. The closed femoral fracture model was also used 
in our previous studies[76, 129]. The standard closed fracture was superior to an 
open osteotomy because this model eliminates the added variable of local wound 
healing[ll]. The closed femoral fracture model resulted in a highly reproducible 
fracture site and configuration with minimal soft tissue trauma[ll] . Moreover, the 
animal costs are still reasonable for larger group studies[99]. 
4.6.3 Inhibit ion of Bone Remodel ing 
As mentioned previously (Section 4.4.1), this inhibition study using ibandronate was 
undertaken in order to study the effect of LMHFV on bone remodeling. Ibandronate 
was administrated weekly on five days post-fracture. As mentioned previously (Sec-
tion 4.1), bone remodeling did not start until three to four weeks after the fracture 
surgery. Therefore, ibandronate might have an effect on both the early fracture 
healing process in addition to bone remodeling during the later phase of fracture 
healing since osteoclast activity begins early in the fracture healing process[125]. As 
mentioned previously (Section Introduction), it is well-studied that bisphosphonate 
inhibits osteoclast activity. However, some studies found that osteoblasts might be 
inhibited by bisphosphonate[63, 66, 123]. Therefore, administration of ibandronate 
five days after fracture surgery might have a negative impact on bone formation 
during the early phase of fracture healing. However, this negative effect was not 
observed in the current in vivo study because there was no significant difference in 
osteocalcin concentration between BG and CG at week 2. Therefore, administra-
tion of ibandronate at the same time as LMHFV treatment would be the optimal 
method. There was no way to determine accurately the stage of fracture healing be-
cause of the significant overlapping between the four stages of fracture healing[130]. 
Also, there might be variation on the initiation of bone remodeling between LMHFV 
and control. Therefore, administration of ibandronate at the same time as LMHFV 
treatment would be the optimal method to ensure inhibition of any enhancement 
by LMHFV on bone remodeling when remodeling begins. 
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4.7 F u t u r e Studies 
4.7 .1 L M H F V Effect on Osteoclast in vitro 
Our current study is an inhibition study in vivo, which studies the effect of LMHFV 
on bone remodeling. A future extension on this study could be repeating this exper-
iment in vitro using osteoclast culture. The best way to obtain mature osteoclast 
is by mechanical isolation from neonatal (age: 2 — 3 days) rat long bone. Various 
osteoclastogenic culture can be obtained from bone marrow cells of young (age: 6 - 9 
weeks) rat bone marrow. These cells are coculture with bone marrow stromal cells 
or cell lines under the stimulation of l,25-dihydroxyvitamin D 3 or dexamethasone, 
or induced by M-CSF and RANKL only[75, 10T]. In addition, small amount of con-
centrated HC1 would be added to the osteoclast culture medium to produce a pH of 
6.95 — 7.0, which is the optimal for resorption pit formation[2]. 
As mentioned previously, LMHFV might inhibit osteoclast activity in the early 
phase of fracture healing (Section 4.2.2), the level of inhibition and apoptosis on 
osteoclast during the early phase of healing would be studied instead of the stimula-
tion on osteoclast activity during the later phase of fracture healing. By plotting a 
dose-response curve by changing one of the parameters of LMHFV treatment, such 
as frequency or acceleration, a better understanding on the effect of LMHFV on os-
teoclast and whether LMHFV stimulates osteoclast directly. To investigate the level 
of inhibition and apoptosis, the osteoclast cell culture will be covered with annexin-
Propidium iodide solution in the dark. The apoptotic osteoclasts will be stained 
by annexin-PI and counted under a fluorescent microscope[75]. The effect on osteo-
clastic activity would be investigated by performing a pit-forming assay. Osteoclast 
culture would be transfered onto dentine slices and stained will 1% toluidien blue 
solution. The number of resorption pits on dentine slices would be counted under 
a light microscope[75]. The resorption lacunae would show a violet colour in bone 
slices after toluidine blue staining[75]. Therefore, the effect of LMHFV on bone 
remodeling and osteoclast would be investigated by using osteoclast cell culture 
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stained with annexin-PI solution and pit-forming assay. 
4.7.2 Biomechanics of Fracture Callus 
As mentioned previously (Section 1.4)，osteoporosis is characterized by decreased 
bone mineral density (BMD) and deterioration in the bone microarchitecture[89]. 
In addition, bone strength is determined by bone volume, microarchitecture of bone, 
and bone mineralization[135]. Therefore, osteoporotic bone are fragile when com-
pared to normal healthy bone. However, in our previous studies, LMHFV enhanced 
the mechanical properties of callus, such as energy to failure and ultimate load, 
in OVX rats to a level that show no significant difference with callus in normal 
LMHFV group[129]. The ultimate load reflects the general integrity of bone while 
energy to failure represents the amount of energy required to break the bone[135]. 
Since there was no significant difference in ultimate load and energy to failure found 
between OVX-LMHFV group and normal-LMHFV group, the mechanical proper-
ties between these two groups may be the same. The biomechanical investigation 
confirms the mechanical properties of the healed callus. Since bone remodeling was 
also enhanced in these studies, the mechanical properties of the fracture femur by 
LMHFV should also be confirmed to be improved. The mechanical properties of 
the callus can be assessed by a four-point bending test. After tested to failure using 
this test, the load-displacement curves of the fracture femora can be generated and 
ultimate load, stiffness, and energy to failure can be measured. 
4.7.3 L M H F V Effect on Leptin-Adrenergic Pathway 
The effect of LMHFV on the leptin-adrenergic pathway might affect fracture healing. 
LMHFV has potential effects on skeletal[64, 82, 106], muscular[42], endocrine[13], 
nervous[106], and vascular systems[83, 70] and also the interactions among systems[106]. 
Therefore, it might be necessary to investigate other signaling pathways which might 
play a role in those systems. Leptin, a peptide hormone synthesized by adipocytes 
that affects appetite and energy metabolism, and adrenergic system are believed to 
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play a role in the control of bone remodeling[12, 22, 114, 143], The central effect of 
leptin seems to be antiosteogenic[22, 26]. LMHFV has shown to reduced serum con-
centration of leptin[84, 118]. Therefore, it would be necessary to investigate whether 
the LMHFV enhanced fracture healing and bone remodeling via reduction of leptin 
expression. 
An in vivo inhibition study, similar to the current study, could be undertaken 
to study the effect of LMHFV on leptin expression. Polyunsaturated Fatty Acid 
(PUFA) was shown to have an effect on the expression of lept in[ l l l , 62，138，105, 
60]. PUFA includes two major compositions of fatty acids: n-3 and n-6 fatty acids 
which found in fish oil and vegetable oil respectively, n-3 fatty acid would decrease 
leptin expression while n-6 would increase leptin expression[lll]. Therefore, treating 
osteoporotic fracture rats with LMHFV in the presence or absence of either n-3 or n-
6, the effect of LMHFV on leptin expression can be investigated. The project might 
provide evidence that the enhanced fracture healing and remodeling by LMHFV 
might be a systematic effect in addition to the local bone effect. In addition, this 
project might provide insights on whether changing the dietary in-take of n-3 and 
n-6 fatty acid would have an effect on fracture healing. 
Chapter 5 
Conclusion 
In conclusion, the question that "Does Low-Magnitude High-Frequency Vibration 
enhance bone remodeling?" is answered in this project. LMHFV enhances bone 
remodeling during fracture healing in osteoporotic rat. This was confirmed by inves-
tigating the changes in bone remodeling under LMHFV in the presence and absence 
of Bis, which was used as a tool to inhibit bone remodeling. LMHFV was able to 
partially reverse the inhibition effect of Bis on bone remodeling. The mechanism of 
the enhanced fracture healing by LMHFV seems to be 
1. LMHFV enhanced bone remodeling by increasing osteoclastic resorption. 
2. LMHFV enhanced bone remodeling by increasing osteoblastic formation. 
3. LMHFV inhibiting osteoclast activity in the early phases of fracture healing 
(pre bone remodeling). 
4. LMHFV accelerated fracture healing in the early phase of healing by enhancing 
callus mineralization and soft callus remodeling. 
5. LMHFV enhanced early callus formation by enhancing osteoblast activity. 
The finding ofthis study might provide evidence that LMHFV might be beneficial to 
patients throughout fracture healing. This study also provided better understanding 
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